Stockwinners Market Radar for December 12, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST PennyMac Financial director Kinsella sells 10,000 common shares - In a regulatory filing, PennyMac Financial director Patrick Kinsella disclosed the sale of 10,000 common shares of the company on December 8 at a price of $79.6053 per share.

19:44 EST Lam Research CEO Archer sells 8,500 common shares - In a regulatory filing, Lam Research president and CEO Timothy Archer disclosed the sale of 8,500 common shares of the company on December 11 at a price of $710.24 per share.

18:54 EST McEwen Mining sees FY23 production 154,200 GEOs - McEwen Mining reported its consolidated production in the October-November period has increased to 29,600 gold equivalent ounces, a significant improvement over the first nine months of the year. In November, Gold Bar production increased to 7,800 gold ounces. As a result of the strong performance at Gold Bar, partially offset by slightly lower production at Fox and San Jose, forecast for the FY23 is now estimated at 154,200 GEOs. "Gold Bar has picked up the pace in the fourth quarter due to higher ore crushing rates combined with an expansion of the heap leach pad, which resulted in a large gold inventory on the heap leach pad starting to produce in October. Monthly production is projected to remain strong in December and into Q1 2024. The additional production from Gold Bar, combined with the announced flow-through equity financing for Fox exploration and development, puts us in a good financial position to enter 2024. Our focus is on driving continued operational improvements and growth projects across the organization," commented Rob McEwen, Chairman and Chief Owner.

18:17 EST Xperi to sell its AutoSense in-cabin safety business to Tobii AB - Xperi announced it has entered into a definitive agreement to sell its AutoSense in-cabin safety business and related imaging solutions to Tobii AB, an eye tracking and attention computing company based in Sweden listed on the Stockholm Nasdaq exchange. Sale proceeds of $42.7M are comprised of a senior secured promissory note in the principal amount of approximately $27.7M carrying a fixed rate of 8% interest to be repaid by Tobii in three annual installments beginning in 2027, and an aggregate of $15M in future cash payments scheduled to be received over four years beginning in 2028. In addition, there is potential incremental contingent cash consideration paid in 2031 directly tied to the success of Tobii's in-cabin safety business over the next seven years. The transaction is subject to customary closing conditions and is expected to close within 30 days. The estimated impact on 2024 revenue is approximately $30M and the transaction is expected to be modestly accretive to Adjusted EBITDA upon closing. The Company expects to issue FY24 guidance in February. Centerview Partners LLC served as exclusive financial advisor for Xperi, and DLA Piper LLP acted as legal advisor.

18:02 EST 17 Education & Technology to change ratio of its ADSs - 17 Education & Technology Group announced that it plans to change the ratio of its American Depositary Shares, or ADSs, to its Class A ordinary shares, par value $0.0001 per share, from the current ADS Ratio of one ADS to ten Class A ordinary shares to a new ADS Ratio of one ADS to fifty Class A ordinary shares, effective on or about December 18. For 17EdTech's ADS holders, the change in the ADS Ratio will have the same effect as a one-for-five reverse ADS split. On the Effective Date, holders of the ADSs will be required to surrender and exchange every five ADSs then held for one new ADS. The Bank of New York Mellon, as the depositary bank for 17EdTech's ADS program, will arrange for the exchange. 17EdTech's ADSs will continue to be traded on the Nasdaq Global Select Market under the symbol "YQ."

17:39 EST XPO approved to buy 28 service centers as part of Yellow's bankruptcy - XPO (XPO) announced that the United States Bankruptcy Court for the District of Delaware has approved the company's offer to acquire 28 service center locations previously operated by Yellow Corporation (YELL). XPO will purchase 26 service centers and assume existing leases for the other two locations. The transaction is expected to close by the end of 2023. Mario Harik, chief executive officer of XPO, said, "This acquisition of real estate is a once-in-a-generation opportunity to increase capacity in critical, growing freight markets, create more jobs and serve our customers even more effectively. We look forward to integrating these prime sites to enhance network efficiency and drive our next decade of growth." The transaction will complement XPO's national network with prime real estate in fast-growing freight markets, including Atlanta, Brooklyn, Columbus, Greensboro, Houston, Indianapolis, Las Vegas, Minneapolis, Nashville, Portland and Central Pennsylvania. Wachtell, Lipton, Rosen & Katz is serving as legal advisor to XPO in connection with this transaction.

17:33 EST Franklin Resources raises dividend 3.3%, adds to stock repurchase plan - Franklin Resources announced a quarterly cash dividend in the amount of 31c per share payable on January 12, 2024 to stockholders of record holding shares of common stock at the close of business on January 3, 2024. The quarterly dividend of 31c per share represents a 3.3% increase over the dividends paid for the prior quarter and the same quarter last year. The company has raised its dividend every year since 1981. Furthermore, the company's Board of Directors has authorized the company to repurchase, from time to time, up to an additional 27.2M shares of its common stock in either open market or private transactions, for a total of up to 40M shares available for repurchase. The new share authorization is in addition to the existing authorization, of which approximately 12.8M shares remained available for repurchase at November 30, 2023. The stock repurchase program is not subject to an expiration date.

17:23 EST Jacobs VP Hill sells $701K in company shares - VP of Jacobs Solutions Patrick Hill disclosed the sale of 5,500 shares of company stock at $127.48 per share on December 8, for a total transaction amount of $701,162.

17:18 EST Cyclacel Pharmaceuticals announces 1-for-15 reverse stock split - Cyclacel Pharmaceuticals biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will implement a 1-for-15 Reverse Stock Split of its common stock , effective at 5:00 p.m. Eastern Time on Friday, December 15, . The Reverse Stock Split, which was approved by stockholders at the Company's Special Meeting of Stockholders on December 8, is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. Beginning with the opening of trading on Monday, December 18, the Company's common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the existing symbol "CYCC" and a new CUSIP number 23254L801.

17:15 EST Lockheed Martin awarded $442.96M Army contract modification - Lockheed Martin was awarded a $442.96M modification to a contract for the Black Hawk helicopter program. Work will be performed in Stratford, Connecticut, with an estimated completion date of June 30, 2027. Fiscal 2024 aircraft procurement, Army funds in the amount of $442.96M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:12 EST JPMorgan's Marianne Lake sells $5.2M in company shares - JPMorgan officer Marianne Lake disclosed the sale of 32,243 shares of company stock at $160 per share on december 12, for a total transaction amount of $5,158,906.

17:08 EST Vermilion Energy sees FY24 FFO C$1.3B - Vermilion Energy announced its 2024 budget and updated return of capital framework, including a 20% dividend increase. Highlights include: 2024 FFO and free cash flow are forecasted to be approximately C$1.3B and C$700M, respectively, based on forward commodity prices; FCF represents an approximately 40% increase versus our 2023 forecast. Sees FY24 capital expenditure budget of C$600M-C$625M includes increased investment in our BC Montney asset and advancement of key growth projects in Germany and Croatia. Sees FY24 production guidance 82,000 - 86,000 boe/d. It reflects a mid-year start-up of the new BC Montney battery and Croatia gas plant and underpins the forecasted 40% increase to FCF. Vermilion continues to provide investors with market diversification as 40% of our 2024 natural gas production will be produced in Europe and receive European gas benchmark pricing, which is approximately six times higher than forward AECO pricing and supports our peer leading netbacks.On November 30 the European Union published a review of the temporary windfall tax and subsequent market developments in the energy sector. The report stated that the situation in energy markets is very different from the exceptional circumstances when the temporary windfall tax was initially established in October 2022, and therefore the European Union has not proposed to extend the mandate beyond 2023. Quarterly cash dividend increased by 20% to C$0.12 per share, effective with the Q1 2024 dividend payable in April 2024. Plan to increase return of capital allocation target to 50% of excess FCF, starting April 1, 2024. When combined, forecasted 40% increase in FCF, the amount of capital allocated to share buybacks in 2024 is expected to double from 2023 levels.

17:01 EST Grainger sells E&R Industrial Sales to Paradigm Equity Partners, no terms - Grainger announced the sale of E&R Industrial Sales to Paradigm Equity Partners, a Los Angeles-based private equity firm. E&R Industrial became a subsidiary of W.W. Grainger in 2013. Grainger will continue to serve customers with maintenance metalworking products, services and expertise while focusing on its core business of maintenance, repair and operating products and services. Customers will continue to have access to E&R's assortment when purchasing through Grainger, while E&R customers will have access to Grainger's MRO-leading assortment when purchasing through E&R. Details of the agreement were not publicly disclosed.

16:43 EST Willdan Group announces retirement of CEO Tom Brisbin and succession plan - Willdan Group announced that on December 8, Tom Brisbin, Willdan's CEO, notified the Board of Directors of his intention to retire from his position as CEO of the company effective December 29. Tom will retain his role as Chairman of the Board and will act as the company's part-time consultant to ensure a smooth transition after December 29. Willdan's President, Mike Bieber, will succeed Tom as CEO and will become a Board Member effective as of December 30. Tom has served as Willdan's CEO since 2007, joining just after the company went public, and growing revenue more than six times over that period. During the 2008 financial crisis, he led the company's expansion into energy efficiency, diversifying into a growing market and adding long-term financial stability. Tom has focused most of his career on developing a culture of organic growth and fostering leadership. Willdan also announced that, in parallel with this transition, Kim Early, Willdan's CFO, and Micah Chen, Willdan's General Counsel, will each be promoted to Executive Vice President, effective December 30.

16:35 EST Codorus Valley Bancorp trading resumes

16:32 EST Autohome CEO Quan Long steps down, Tao Wu to succeed - Autohome announced that Quan Long has stepped down from his position as the CEO of the company due to his other personal commitments, effective immediately. Long will remain in his position as the chairman of the board of directors of the company. Dr. Jing Xiao has also resigned from his position as a director and a member of the Nominating and Corporate Governance Committee of the Board due to his other personal commitments, effective immediately. The company is pleased to announce that Tao Wu has been appointed as an executive director of the company and the CEO, and Keke Ding, a current director and member of the Compensation Committee of the Board, has been appointed as a member of the Nominating and Corporate Governance Committee of the Board, both effective immediately. Tao Wu has over 28 years of experience in the property and casualty insurance and automobile services industries. Wu currently serves as a director of Ping An Property & Casualty Insurance Company of China, Ltd

16:31 EST NuZee appoints Randell Weaver as COO - NuZee announced Randell Weaver has been appointed to serve as the company's President and COO, effective immediately. As President & COO, Weaver will have responsibility for all U.S. operations. Weaver joined the company in August 2023 as Chief Financial Officer and will also continue to serve in that role. Weaver has more than 30 years of well-rounded manufacturing, distribution, and CPG experience with three prior terms as a public company President, COO or CFO and demonstrated success in cash management, fund raising, building and mentoring staff, structuring financing options, optimizing performance, growth, strategic planning and relationship management. Prior to joining NuZee, Weaver served as CFO of Reinvention Unlimited, providing financial and operational management, mentoring and executive oversight services for international manufacturing and distribution clients with a focus on regulated industries in food, pharmaceuticals and contracting. Before that, he held several key positions, including CFO of a publicly held CPG manufacturing and distribution company with international operations and units in baked organic baby foods, nutritional supplements, and highly regulated cannabis products. While there, he transitioned that issuer's listing from TSX to NASDAQ and helped raise in excess of $15M in debt and equity. Weaver previously held interim management positions at a private equity-acquired food packaging company and a frozen food company.

16:29 EST Cal-Maine reports positive test result for avian influenza at Kansas facility - Cal-Maine Foods reported that one of the company's facilities in Kansas tested positive for highly pathogenic avian influenza, affecting approximately 684,000 laying hens, or approximately 1.6% of the company's total flock. Production at the facility has temporarily ceased as the Company follows the protocols prescribed by the USDA. Cal-Maine Foods is working to secure production from other facilities to minimize disruption to its customers. According to the USDA, these detections do not present an immediate public health concern and are not a threat to the food supply. Also, according to the USDA, HPAI cannot be transmitted through safely handled and properly cooked eggs or poultry. There is no known risk related to HPAI associated with eggs that are currently in the market and no eggs have been recalled. There have been no positive tests for HPAI at any other Cal-Maine Foods locations to date. Cal-Maine Foods believes it has implemented and continues to maintain robust biosecurity programs across all its locations. Additional strict protocols are in place designed to prevent exposure from the Kansas facility to other locations, including the Company's nearby layer complex which houses approximately one million hens. The Company continues to work closely with federal, state and local government officials and focused industry groups to mitigate the risk of future outbreaks and effectively manage the response.

16:24 EST RPT Realty shareholders approve mergers - RPT Realt announced that at a special meeting of the shareholders of RPT the RPT shareholders approved the proposal necessary for the closing of the previously announced mergers pursuant to the Agreement and Plan of Merger, dated as of August 28 by and among Kimco Realty Corporation Tarpon Acquisition Delaware limited liability company and a direct wholly owned subsidiary of Kimco etc, will merge with and into RPT OP, with RPT OP surviving the partnership merger PT will merge with and into Merger Sub with Merger Sub surviving the Company Merger as a wholly owned subsidiary of Kimco and immediately after the Company Merger, Kimco will contribute all outstanding membership interests of Merger Sub to Kimco OP. At the Special Meeting, approximately 99.8% of the votes were cast for the approval of the Company Merger and the other transactions contemplated by the Merger Agreement, which represented approximately 87.6% of outstanding RPT common shares, including restricted shares, as of November 1 the record date of the Special Meeting.The final voting results will be reported on a Form 8-K filed with the Securities and Exchange Commission by RPT with respect to the Special Meeting. The Mergers are expected to close on January 2, subject to the satisfaction or waiver of customary closing conditions.

16:21 EST Americold Realty Trust to build, operate new $35M cold storage facility - Americold Realty Trust announced plans to build and operate a new $35M cold storage facility with 40,000 pallet positions, in the Jebel Ali Free Zone in the Port of Jebel Ali in Dubai. This investment builds on the strategic collaboration between Americold and DP World, a provider of worldwide smart end-to-end supply chain logistics with a global port infrastructure. The new facility will offer multi-temperature capabilities and connect to DP World's logistics solutions. Earlier this year, RSA Cold Chain entered into a long-term land lease agreement with DP World to support this development. Construction will start early 2024 and is expected to be completed by Q1 of 2025.

16:19 EST Tandem Diabetes announces full U.S. launch of Tandem Source - Tandem Diabetes Care announced the launch of Tandem Source, a diabetes management platform for insulin pump users and healthcare providers (HCPs). Tandem Source is designed to bring together the features of Tandem's legacy t:connect, t:connect HCP, and t:connect Portal offerings with new comprehensive data reporting in one central, scalable platform. Tandem Source is now available for all Tandem pump users and their HCPs in the United States, with international availability expected in 2024.

16:16 EST RB Global appoints Eric Guerin as CFO - RB Global announced the appointment of Eric J. Guerin as CFO, effective January 15, 2024. Guerin brings extensive senior executive financial leadership experience, most recently serving as the CFO of Veritiv Corporation, a leading distributor of packaging, facility solutions and print products, until its acquisition in November of 2023. Prior to Veritiv, Guerin served as Executive Vice President and Chief Financial Officer of CDK Global, Inc., a provider of retail technology and software-as-a-service solutions to the automotive, heavy truck, recreation, and heavy equipment industries. Guerin previously served as Division Vice President, Finance for Corning Incorporated, a provider of specialty glass, ceramics and related materials and technologies for industrial and scientific applications. Earlier in his career, Guerin served in a number of financial management roles for various public companies, including Flowserve Corporation, Novartis and Johnson & Johnson. Guerin currently serves as a member of the board of directors for Skyworks Solutions, Inc., an innovator of high-performance analog semiconductors connecting people, places and things, and previously served on the Board of Directors of Natus Medical, a provider of medical equipment, software and services.

16:15 EST ReShape Lifesciences: FDA approves a PMA supplement for Lap-Band 2.0 FLEX - ReShape Lifesciences announced that the U.S. Food and Drug Administration FDA has granted approval of a PMA supplement for the company's next generation, enhanced Lap-Band 2.0 FLEX. "PMA supplement approval for our next generation Lap-Band 2.0 FLEX is a historic event for ReShape that is expected to be a key growth catalyst for the company's Lap-Band franchise," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. "The enhanced Lap-Band 2.0 FLEX development effort was physician-led with the goal of improving the patient experience. Compared to our current Lap-Band, the Lap-Band 2.0 has a new feature called FLEX Technology, which acts as a relief valve, allowing larger pieces of food to more easily pass through the narrowed passage or stoma , created by the band. Specifically, the band momentarily relaxes before returning to its resting diameter, therefore, minimizing discomfort caused by passage of large food pieces through the stoma. The Lap-Band system is the safest and most durable weight loss option for obese patients and is ideal for those who are averse to medically managed weight loss and who opt for the only available anatomy preserving surgery. We are preparing for our U.S. product launch of the Lap-Band 2.0 FLEX and look forward to providing updates on our progress."

16:11 EST Fuel Tech awarded APC and Chemical Technologies orders totaling $2.5M - Fuel Tech announced the receipt of air pollution control and Chemical Technologies orders from existing customers in South Africa and the Caribbean. These awards have an aggregate value of approximately $2.5M. An order was received from an existing customer for an industrial unit in South Africa using electrostatic precipitators to collect and recover particulate emissions. The contract was for two Dual Flue Gas Conditioning systems to improve particulate capture from ESPs at an ore processing facility. Dual FGC technology uses sulfur trioxide and ammonia as conditioning reagents to improve the efficiency of ESPs, which are used to capture fly ash particulate from coal-fired boilers and particulate from industrial processes. FGC systems provide a low capital cost approach to improving particulate capture by maximizing the collection efficiency of new or existing ESPs. Dual FGC technology with ESPs can help units meet regulatory requirements for particulate and opacity levels, without the investment of significant additional capital, and are an attractive alternative to fabric filter technology. The project scope includes the overall FGC system engineering, supply of key FGC equipment, critical ESP components along with FGC startup support for the project. Fuel Tech is working with a local project partner in South Africa who is supplying the basic FGC equipment and providing the installation scope for the project. Equipment deliveries are expected to be completed in the third quarter of 2024, with project startup expected in the first quarter of 2025.

16:07 EST Caribou Biosciences provides regulatory update on CB-010 development program - Caribou Biosciences provided an update based on feedback from the FDA following recent communications and a Type B clinical meeting regarding the CB-010 development program. The company has received the FDA's feedback on a Phase 3 randomized controlled trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy in development for patients with second-line relapsed or refractory large B cell lymphoma, or r/r LBCL. The FDA stated that Caribou's proposed comparator arm of platinum-based immunochemotherapy followed by high dose chemotherapy, or HDCT, and autologous stem cell transplantation, or ASCT, is acceptable. In the ongoing ANTLER Phase 1 trial, Caribou is enrolling second-line LBCL patients in the dose expansion portion based on promising data from the dose escalation portion of the trial. Currently, 22 sites are active in the U.S. and the first international site is active in Australia, with additional site activation underway in the U.S. and globally. To Caribou's knowledge, CB-010 is the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the second-line LBCL setting and it has been granted Regenerative Medicine Advanced Therapy, or RMAT, Fast Track, and Orphan Drug designations by the FDA. In Q2, the company plans to report initial dose expansion data from the ANTLER trial and share the recommended Phase 2 dose for CB-010. Caribou plans to initiate a Phase 3 pivotal trial with this RP2D by year-end 2024.

16:06 EST C4 Therapeutics says CFT7455 monotherapy shows signs anti-myeloma activity - C4 Therapeutics C4T presented clinical data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of CFT7455, a MonoDAC degrader of IKZF1/3, for the potential treatment of multiple myeloma MM and non-Hodgkin's lymphomas NHL . These data include results from CFT7455 as a monotherapy for relapsed/refractory R/R MM patients, which has completed dose escalation, and interim results from CFT7455 in combination with dexamethasone for R/R MM patients, which continues to enroll patients. C4T also continues to enroll patients in the Phase 1 dose escalation trial exploring CFT7455 as a monotherapy for NHL patients. "We are excited CFT7455 monotherapy is showing promising signs of anti-myeloma and immunomodulatory activity and anti-myeloma activity when combined with dexamethasone, particularly in patients who have undergone numerous lines of prior therapy for multiple myeloma, including BCMA therapies," said Len Reyno, M.D., chief medical officer of C4 Therapeutics. "We have established 14 days on/14 days off as the optimal dosing schedule, which is consistent with our preclinical data supporting CFT7455 as a rationally designed IKZF1/3 degrader with the potential to offer a new therapy for patients with relapsed/refractory multiple myeloma."

16:01 EST Codorus Valley Bancorp trading halted, news pending

14:35 EST Netflix issues first bi-annual engagement report on viewing - In a blog post, Netflix stated: "Since launching our weekly Top 10 and Most Popular lists in 2021, Netflix has provided more information about what people are watching than any other streamer except YouTube. And now we believe it's time to go further. Starting today we will publish 'What We Watched: A Netflix Engagement Report' twice a year. This is a comprehensive report of what people watched on Netflix over a six month period, including: Hours viewed for every title - original and licensed - watched for over 50,000 hours; The premiere date for any Netflix TV series or film; and Whether a title was available globally. In total, this report covers more than 18,000 titles - representing 99% of all viewing on Netflix - and nearly 100 billion hours viewed. Over 60% of Netflix titles released between January and June 2023 appeared on our weekly Top 10 lists. So while this report is broader in scope, the trends reflected in it are very similar to those in the Top 10 lists... This is a big step forward for Netflix and our industry. We believe the viewing information in this report - combined with our weekly Top 10 and Most Popular lists - will give creators and our industry deeper insights into our audiences, and what resonates with them." Reference Link

13:57 EST Marsh McLennan unit Oliver Wyman acquires SeaTec Consulting - Oliver Wyman, a business of Marsh McLennan, announced that it has entered into an agreement to acquire SeaTec Consulting, a provider of consulting, engineering, and digital expertise across the aviation, aerospace and defense, and transportation industries. SeaTec will join Cavok, a division of Oliver Wyman, focused on aviation services. The transaction is expected to close in Q1 of 2024.

13:16 EST Panasonic in deal with battery materials maker Sila for Titan Silicon. no terms - Panasonic Energy announced the signing of a commercial agreement for Sila's high-performance nano-composite silicon anode, Titan Silicon. The high energy density battery from Panasonic is expected to enable automakers to deliver unmatched EV performance, dramatically increasing vehicle range and reducing charge times. Sila's anode materials, to be produced in the company's plant in Moses Lake, WA, will be optimized for Panasonic's next-generation lithium-ion batteries. "By integrating Sila's groundbreaking battery material with our advanced cell manufacturing capabilities, we believe that we can address the concerns such as range anxiety and charging time and contribute to accelerating the adoption of EVs," said Shoichiro Watanabe, Executive Vice President of Panasonic Energy.Companies that are in the EV battery space include Tesla (TSLA). Reference Link

12:35 EST Adit EdTech Acquisition Cor trading resumes

12:11 EST J&J: Data from Phase 3 PERSEUS study shows improvement in outcomes for patients - Johnson & Johnson announced the first data from the Phase 3 PERSEUS study highlighting significant clinical improvement with a DARZALEX FASPRO-based quadruplet induction, consolidation regimen and doublet maintenance regimen in the treatment of transplant-eligible newly diagnosed multiple myeloma. The data, showing an unrivaled progression-free survival in a Phase 3 study evaluating TE NDMM and clinically significant improvement of rates of overall complete response or better and minimal residual disease negativity over the comparator arm, were featured as a late-breaking oral presentation at the 2023 American Society of Hematology Annual Meeting. The data were published simultaneously in The New England Journal of Medicine. The PERSEUS study, conducted in collaboration with the European Myeloma Network, found that induction and consolidation treatment with DARZALEX FASPRO in combination with bortezomib, lenalidomide and dexamethasone, followed by DARZALEX FASPRO(R) and lenalidomide maintenance, reduced the risk of disease progression or death by 58 percent, compared to bortezomib, lenalidomide and dexamethasone alone followed by lenalidomide maintenance.1 The quadruplet regimen also significantly increased the depth of response compared to treatment with VRd alone, with higher rates of CR or better, stringent complete response, and MRD negativity. The estimated 48-month PFS rates were 84.3 percent for D-VRd vs 67.7 percent for VRd. The overall safety profile of D-VRd was consistent with the known safety profiles for daratumumab and VRd.

12:06 EST Syndax says AUGMENT-101 trial of revumenib met primary endpoint - Syndax Pharmaceuticals presented data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial of revumenib, a menin inhibitor, in adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia at the 65th American Society of Hematology Annual Meeting being held December 9-12, 2023 in San Diego, California. The pivotal results were featured in a late-breaking oral presentation titled "Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study." Additional supportive results from the AUGMENT-101 trial, including data from patients in the Phase 1 portion and patients who received revumenib maintenance therapy after hematopoietic stem cell transplant, were also featured in two poster presentations at the meeting, titled "Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Efficacy and Safety Results from the AUGMENT-101 Phase 1/2 Study" and "Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant." The AUGMENT-101 trial met its primary endpoint at the protocol-defined interim analysis with a complete remission or a CR with partial hematological recovery rate of 23% among the 57 efficacy evaluable patients in the pooled KMT2Ar acute leukemia population. The CR/CRh rate was 23% in adult patients and 23% in pediatric patients, with a median time to CR/CRh of 1.9 months. The CR/CRh responses in both the overall population and the AML subset were durable with a 6.4-month median duration as of the July 24, 2023 data cutoff, with 46% remaining in response. Minimal residual disease status was assessed in 10 of the 13 patients who achieved a CR/CRh, 70% of whom were MRD negative. In patients who achieved a CRc, 68% achieved MRD negative status. In the efficacy-evaluable patients, the overall response rate was 63%, and the composite response rate was 44%. Minimal residual disease status was assessed in 22 of the 25 patients who achieved a CRc, 68% of whom were MRD negative. Responses were observed in all major subgroups, including across the number of prior treatments and prior stem cell transplant. A total of 14 patients who achieved an overall response underwent HSCT, eight of whom did not achieve a CR or CRh prior to transplant. Half of the patients who had an HSCT received post-transplant maintenance with revumenib and three additional patients were in follow-up and are eligible to restart revumenib as post-transplant maintenance. Median overall survival at the time of data cutoff was 8.0 months. AUGMENT-101 enrolled a total of 94 acute leukemia patients in the KMT2Ar cohorts of the pivotal trial as of the July 2023 data cutoff, 57 of whom had central confirmation of their KMT2Ar status, sufficient follow-up and were in the efficacy-evaluable population. The majority of patients included in the efficacy-evaluable population relapsed following treatment with at least one salvage regimen prior to enrollment, including nearly half having undergone prior stem cell transplant. Seventy-two percent of patients were previously treated with venetoclax. Revumenib was well tolerated and the safety profile was consistent with the Company's previously reported data. Treatment-related adverse events leading to dose reductions and treatment discontinuation were low at 9% and 6%, respectively. TRAEs of any grade in greater than 20% of patients included nausea, differentiation syndrome, and QTc prolongation. Grade 3 DS was observed in 15% of patients while one patient experienced Grade 4 DS and no patients experienced a Grade 5. Grade 3 QTc prolongation was observed in 14% of patients, with no Grade 4 or 5 events. There were no discontinuations related to DS, cytopenias or QTc prolongation on the trial.

12:01 EST Integra LifeSciences names 3D Systems CEO Jeff Graves to board - Integra LifeSciences Holdings Corporation (IART) announced that Jeff Graves, Ph.D., president and CEO of 3D Systems (DDD), was appointed to the company's board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 2021. "I am pleased to welcome Jeff to our board of directors. He is a highly-accomplished executive with a track record of leading and transforming technically complex businesses," said Stuart Essig, chairman of the Integra board of directors. "His experience in streamlining global operations to deliver differentiated solutions to markets, including healthcare, will be valuable assets to the board and enable Integra to continue driving shareholder value."

12:00 EST Harmony Gold falls -9.9% - Harmony Gold is down -9.9%, or -60c to $5.50.

12:00 EST Eagle Bulk Shipping rises 11.8% - Eagle Bulk Shipping is up 11.8%, or $5.47 to $51.66.

12:00 EST Gaotu Techedu rises 14.7% - Gaotu Techedu is up 14.7%, or 43c to $3.36.

11:32 EST Acri Capital reports extension to deadline for initial business combination - Acri Capital Acquisition Corporation, a special purpose acquisition company, announced that, in order to extend the date by which the company must complete its initial business combination from December 14, 2023 to January 14, 2024, Acri Capital Sponsor LLC, the sponsor of the company, has deposited into its trust account an aggregate of $75,000. Pursuant to the company's Amended and Restated Certificate of Incorporate currently in effect, the company may extend on monthly basis from July 14, 2023 until April 14, 2024 or such an earlier date as may be determined by its board to complete a business combination by depositing the New Monthly Extension Payment for each month into the Trust Account.

11:15 EST EF Hutton Acquisition Corp trading resumes

11:05 EST EF Hutton Acquisition Corp trading halted, volatility trading pause

11:01 EST Rumble says services are 100% restored - In a Monday tweet, Rumble said, "Services are 100% restored. A major thank you to our cyber security partners and our entire team. This was a massive learning experience that will only make us stronger. A big thank you to all users and creators who have been incredibly patient with us during this time." Reference Link

10:44 EST HUB Security announces 1-for-10 reverse share split - Hub Cyber Security Ltd. announced a 1-for-10 reverse share split of its ordinary shares, no par value per share. The reverse share split and corresponding share capital adjustment will become effective at 11:59 p.m. Eastern Time on December 14, 2023.

10:34 EST CoreSite announces expansion of New York, Denver data center campuses - CoreSite announced the expansion of its New York and Denver strategic data center campuses to meet growing capacity and power demands of public and private cloud providers, enterprises, network and service providers. CoreSite's latest New York campus data center received final permitting to complete construction of the 85,000-square-foot facility and 15 critical megawatts of capacity. CoreSite has also received conceptual approval for a three-building data center campus development of approximately 600,000 square feet and 60 CMW of capacity in the Denver market. Construction of NY3 is expected to be completed in Q4 2024.

10:17 EST General Motors, Komatsu collaborate on hydrogen fuel cell-powered mining truck - General Motors (GM) and Komatsu (KMTUY) will co-develop a hydrogen fuel cell power module for Komatsu's 930E electric drive mining truck, the world's best-selling ultra-class haul truck. GM and Komatsu will jointly design and validate the technology. "At GM, we believe fuel cells can play an integral role in a zero-emissions future, helping to electrify heavier-duty applications, beyond passenger vehicles," said Charlie Freese, executive director of GM's Global HYDROTEC business. "Mining trucks are among the largest, most capable vehicles used in any industry, and we believe hydrogen fuel cells are best suited to deliver zero emissions propulsion to these demanding applications." Komatsu has set a target of reducing its global emissions by 50% by 2030 and a challenge target of achieving carbon neutrality by 2050. GM's target is to be fully carbon neutral in both products and operations by 2040.

10:08 EST eBay introduces limited-time consignmnent concierge - eBay is rolling out a mobile consignment concierge, the company announced on Tuesday, commenting: "The Luxe Line - a branded bus offering people a physical place to sell their luxury accessories, as well as shop for new ones - demonstrates the simplicity of the platform's recently launched eBay consignment service. Visitors in Los Angeles and Las Vegas will have direct access to expert sellers who list and sell their luxury items on their behalf." "Our consignment service is designed to help to remove the typical barriers to selling pre-owned items," said Tirath Kamdar, Global GM of Luxury at eBay. "The Luxe Line gives sellers and shoppers a way to test out our new service in real life with the same trusted experts that eBay works with for the online experience."

10:06 EST Petros Pharmaceuticals completes Human Factors Study for STENDRA - Petros Pharmaceuticals announces the completion of a Human Factors Study, whose objective was to assess the technology component developed to facilitate patient's access to its erectile dysfunction drug, STENDRA, associated with the Company's intended FDA application for prescription to OTC switch. The objective of the study was to determine the strengths and weaknesses of the interface of a developmental technology tool, as well as potential use errors in critical tasks, such as navigating and reporting medical history, entering birth date and other key call to action prompts. These tasks, if performed incorrectly - or not performed at all - have the potential to contribute to inappropriate use by the patient or user. The results of the study showed that most participants were able to navigate the tool correctly. Data from the study provided an opportunity for the Company to further optimize this technology, including reformatting of text to improve interaction, which Petros intends to implement in future studies, including additional Human Factor Studies and Self Selection studies. These components are all integral to FDA guidelines for technology-driven OTC access to medications.

10:03 EST NASA chooses Ball Aerospace for CMEx mission concept study - Ball Aerospace was selected to manage a concept study for NASA's Chromospheric Magnetism Explorer, a proposed mission concept that could provide new insights into how magnetism drives eruptive activity on and near the surface of the sun. The science of CMEx aims to help the scientific community better its understanding of our sun and its impacts on space, Earth and other planets. The prospective mission concept would use a near ultraviolet spectropolarimeter as its primary scientific instrument to make novel observations of the sun's magnetic field as it evolves from the photosphere through the chromosphere, the layer of the sun's atmosphere above the visible surface. This data will give scientists a better understanding of how magnetic energy buildup leads to eruptions such as solar flares and coronal mass ejections, a major gap in our current heliophysics research capabilities.

10:01 EST Baker Hughes appoints Georgia Magno as CLO - Baker Hughes announced Georgia Magno as chief legal officer effective Jan. 1, 2024. She will be responsible for the Company's legal and regulatory affairs, corporate governance, and compliance functions. Magno previously served as vice president and general counsel for Baker Hughes' Industrial & Energy Technology business segment.

10:00 EST SilverBow Resources falls -9.4% - SilverBow Resources is down -9.4%, or -$2.81 to $27.14.

10:00 EST Torrid rises 9.2% - Torrid is up 9.2%, or 44c to $5.21.

10:00 EST Gaotu Techedu rises 13.5% - Gaotu Techedu is up 13.5%, or 40c to $3.33.

09:49 EST Wyndham confirms receipt of 'highly conditional' offer from Choice Hotels - Wyndham Hotels & Resorts (WH) confirmed that Choice Hotels International (CHH) has commenced an unsolicited exchange offer to acquire all outstanding shares of Wyndham common stock. "The offer proposed by Choice appears unchanged from the terms outlined in a letter to Wyndham dated November 14, 2023 and is currently valued at approximately $86 per share," Wyndham stated. "Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, the Wyndham Board of Directors will carefully review and evaluate the offer to determine the course of action that it believes is in the best interests of Wyndham and its shareholders. However, the offer looks to be unchanged from Choice's previous highly conditional offer the Board reviewed and rejected, which failed to address the serious concerns repeatedly expressed by Wyndham, including: The asymmetrical risk to Wyndham shareholders given the uncertainty around antitrust approval (if any) and the estimated 24-month timeline previously cited by Choice; The undervaluation of Wyndham's superior, standalone growth prospects; and the value of Choice shares relative to its growth prospects and further compromised by elevated levels of leverage that this deal would require. In addition to the 10 Wyndham shares they previously disclosed, Choice today announced ownership of less than 1.7% of Wyndham common stock and conceded they are restricted from further purchases without antitrust approval. The Board intends to advise shareholders of its recommendation regarding the offer within ten business days by making available to shareholders and filing with the U.S. Securities and Exchange Commission a recommendation statement on Schedule 14D-9. Wyndham shareholders are urged not to take any action with respect to the offer until the Board announces its recommendation," Wyndham stated in a press release.

09:47 EST SilverBow Resources falls -9.3% - SilverBow Resources is down -9.3%, or -$2.79 to $27.16.

09:47 EST ProShares UltraShort Bloomberg Natural Gas rises 7.2% - ProShares UltraShort Bloomberg Natural Gas is up 7.2%, or $7.53 to $112.85.

09:47 EST Taro Pharmaceutical rises 7.6% - Taro Pharmaceutical is up 7.6%, or $2.87 to $40.80.

09:36 EST Intchains Group Ltd (ADR) trading halted, volatility trading pause

09:30 EST WTW launches CyProtect Bermuda - WTW announced the launch of CyProtect Bermuda, a cyber insurance product designed and tailored to be a comprehensive solution for financial, professional, and executive risks. Targeted towards large enterprises operating in the Bermuda market, CyProtect Bermuda is setting a new standard, delivering fortified coverage, streamlined processes, and exclusive advantages to shield corporations from the ever-changing cyber threat landscape.

09:30 EST Smith-Midland Corp receives $3.8M J-J Hooks barrier rental contract - Smith-Midland Corporation has begun renting its J-J Hooks precast concrete barrier to the Virginia Department of Transportation, as part of the I-64 Gap Widening Project in New Kent County, Virginia. The total value of the project through its Concrete Safety Systems rental division is approximately $3.8 million.

09:25 EST Neonode to focus on licensing business - Neonode announced a new, sharpened strategy with full focus on its licensing business. Consequently, Neonode will phase out its Touch Sensor Module - TSM - product business through licensing of the TSM technology to strategic partners or outsourcing. The focus will be on licensing of the advanced MultiSensing platform for driver and in-cabin monitoring and the proven optical sensing technology zForce, including TSM technology, which supports touch, gesture sensing, as well as object detection features. Neonode will focus all its efforts and resources on licensing by reallocating marketing, sales, and engineering resources from the product team to the licensing team and by external recruitments. The new strategy will lead to some reductions in the workforce, which mainly will affect consultants and personnel in Sweden and involves customary union negotiations.

09:24 EST PubMatic appoints Jones to board of directors - PubMatic announced the appointment of Ramon Jones, Executive Vice President and Chief Marketing Officer of Nationwide Mutual Insurance Company, to the PubMatic Board of Directors. Jones brings over three decades of marketing and business operations leadership to his new role at PubMatic.

09:20 EST PHI Group signs agreement with Dat Minh Doan for 'pure energy' solutions - PHI Group announced that the Company has signed an Agreement for Comprehensive Cooperation with Eng. Dat Minh Doan, a geomagnetic and quantum physics expert to jointly cooperate in applying Mr. Doan's proprietary inventions that are specifically designed to exploit the earth's available geomagnetic energy to generate "pure energy" and store energy without using an energy storage system. According to the Agreement, both parties agree to use Philux Global Energy, Inc., a Wyoming corporation and wholly-owned subsidiary of Philux Global Group, Inc., Registration Number 2022-001066221, incorporated January 3, 2022, as the operating company to commercialize energy-related products based on the results of Eng. Doan's 40 years of proprietary researches and developments, including producing and providing generators using the earth's available geomagnetic energy, producing engines powered by the earth's available geomagnetic energy, as well as developing additional multiple new technologies. Eng. Doan's core technologies include Schumann magnetic resonance, utilizing energy from lightning in the ionosphere, natural storage in the atmosphere as Energy Storage Systems, acceleration of Muon particles in the module, taking advantage of wave nodes and wave troughs in the process of transmitting energy in the form of multi-frequency impulses. According to Eng. Doan, the distinctive advantages of this "Pure Energy" system include: not depending on weather conditions, does not require much land and/or water surface, no need for large space - system can be compactly packed in two 40-foot containers for each MW, easy to transport, electromagnetic compatibility with living organisms and humans, no harm effects to the health of humans, livestock, pets, or vegetation, no waste or greenhouse gas emissions, no heat generation, no noise generation, easy know-how protection with quantum encryptions, easy to set up virtual power plants by using proprietary modules to coordinate output synchronously, easy to establish wireless power transmission systems with huge capacity without heat loss at close range, suitable setup for two-way recharging for electric cars. Eng. Doan will serve as the Chief Technology Officer of Philux Global Energy, Inc. and transfer intellectual properties related to energy generation and energy storage using the earth's available geomagnetic energy to Philux Global Energy, Inc. to be patented jointly for commercialization. He will hold fifty percent of the initial Common Stock of Philux Global Energy, Inc. Both parties mutally warrant that the intellectual properties and technologies that have been developed and will have been developed by Eng. Doan shall never be used for warfare purposes under any circumstances. In addition, Philux Global Group, Inc. is committed to spinning off and listing Philux Global Energy, Inc. in the U.S. Stock Markets, particularly Nasdaq, within one year or as soon as possible based on the progress and growth of this subsidiary.

09:17 EST LanzaTech, Tadweer join forced to initiate integrated Waste-to-SAF study - LanzaTech Global and Tadweer have joined forces to initiate an integrated Waste-to-Sustainable Aviation Fuel, SAF, feasibility study to scale SAF production from municipal and commercial solid waste. This is the first major project in LanzaTech and Tadweer's partnership and forecasts that up to 350,000 tonnes of hard-to-recycle municipal and commercial solid waste per year can be transformed into 200,000 tonnes of ethanol per year, ultimately producing 120,000 tonnes of SAF annually. Jennifer Holmgren, Chief Executive Officer of LanzaTech, commented: "Recycling municipal solid waste, rather than letting it pile up in landfills, offers incredible potential to produce sustainable aviation fuel at scale and reduce air travel's carbon footprint. This solution creates an alternative, lower carbon supply chain. With LanzaTech's technology in Tadweer's facilities, this project is an opportunity to address the climate crisis on two fronts simultaneously and keep virgin fossil fuels in the ground."

09:16 EST Cassava Sciences announces dividend distribution of warrants to shareholders - Cassava Sciences announced a pro rata dividend distribution of warrants to holders of the Company's common stock as of December 22, 2023. Shareholders will receive 4 warrants for each 10 shares of common stock held as of the Record Date, subject to rounding. Cassava Sciences will distribute the warrants to shareholders on or about January 3, 2024. After the Distribution Date, the warrants are expected to list and trade on Nasdaq, separate from Cassava Sciences' common stock, under the ticker SAVAW. Stockholders will receive 4 warrants for each 10 shares of common stock held as of the Record Date, rounded down to the nearest whole number for any fractional warrant. As an example, a shareholder who owns 1,000 shares of Cassava Sciences will receive 400 warrants plus, as applicable and as described below, the Bonus Share Fraction. Each warrant will entitle the holder to purchase, at the holder's sole and exclusive election, one share of common stock at an initial exercise price of $33.00 per share plus, as applicable and as described below, the Bonus Share Fraction. After the Distribution Date, warrant holders may cash-exercise their warrants, or they may sell their warrants on the open market. The Company will receive cash proceeds only from warrant holders who exercise their warrants. Warrant holders may exercise their warrants as will be specified under the terms of a warrant agreement that is expected to be filed with the U.S. Securities and Exchange Commission on or about January 3, 2024.

09:14 EST Lottery.com names Matthew McGahan as president, CEO, Gregory Potts as COO - Lottery.com announces the following strategic leadership appointments. Matthew McGahan assumes the helm as CEO, President, and Secretary, while Gregory Potts steps into the role of COO. McGahan, previously serving as interim CEO since July 2023, brings a wealth of diverse experience to Lottery.com. Gregory Potts, promoted to COO, will oversee the reinvention of Lottery.com's commercial growth and global operations. His extensive 25-year experience in strategic growth and marketing, coupled with his recent success as Global Vice President of Affiliate Success at Lottery.com, positions him to lead sales, marketing, customer success, and business development.

09:11 EST Viewpoint Creative secures multi-year design, animation contract - Viewpoint Creative announced its extensive partnership with the Massachusetts State Lottery, specializing in digital graphic design and animation services. The agreement builds on the success of yesterday's state-wide launch of the redesigned presentation of the Mass Lottery's Keno game. The focus of Viewpoint's services will primarily revolve around enhancing the Mass Lottery's monitor game product line, encompassing both design updates for existing games and the potential creation of graphics for new game launches. Viewpoint Creative is already well underway with its initial collaboration with the Mass Lottery, where they are in the process of refreshing the visual identity of Keno, one of the state's most beloved games. Their aim is to modernize the game while preserving its familiar user experience.

09:09 EST CarMax introduces first all-electric semi-truck into logistics fleet - CarMax announces the pilot of its first all-electric semi-truck that is being used as a vehicle hauler in California's San Joaquin Valley. The truck can transport up to seven vehicles at one time and can travel an estimated 230 miles on a single charge, enabling it to efficiently service CarMax's stores in the region. CarMax is testing the all-electric semi-truck in real-world conditions and its Stockton, California store will serve as the region's hub for fast-charging the vehicle with a Level 3 charging station.

09:07 EST Scilex announces expanded access to ELYXYB - Scilex Holding announced that it has signed an insurance coverage agreement for ELYXYB with a national PBM, for their Medicare population potentially expanding coverage of ELYXYB. "We are pleased to report solid ELYXYB growth in managed plans for additional points of care and expanded utilization of ELYXYB throughout the U.S. Importantly, our diversified portfolio of unique products will increasingly allow us to offer patients complementary and standalone opioid-sparing pain management solutions. The Scilex commercial team continues to demonstrate success in expanding access and currently has prioritized and targeted select payor accounts to improve the access for ELYXYB(R)," said Jaisim Shah, Chief Executive Officer and President of Scilex.

09:06 EST NeuroMetrix reports results from pilot trial of Quell in post-acute covid-19 - NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with post-acute COVID-19 syndrome, commonly called Long COVID. The presentation was made at the National Science Foundation funded Center to Stream Healthcare In Place annual meeting in Washington DC. The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP. The principal investigator was Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine. The Quell PACS study was a subject and investigator blinded, randomized, sham-controlled trial. Twenty-five subjects completed the study. The trial met the BPI primary endpoint, with the pain interference subscale exhibiting a greater decrease in the active arm compared to the sham arm. In the 60% of subjects who met ACR criteria for fibromyalgia, the MAF showed a significant within-group decrease in fatigue for the active arm but not for sham. The active group also demonstrated significant within-group improvements in gait quality. "The impact of COVID-19 lingers long after the acute infection in many individuals, and may resemble a fibromyalgia-like syndrome. Unfortunately, like traditional fibromyalgia, the COVID-19 version is debilitating and difficult to treat," said Shai Gozani, M.D., Ph.D., CEO of NeuroMetrix. "This pilot trial suggests that Quell may alleviate fibromyalgia-like pain and other symptoms of Long Covid. We are conducting a regulatory review to determine if the data supports an expansion of the Quell fibromyalgia label. We appreciated the opportunity to work with Professor Bijan Najafi and his colleagues at the Baylor College of Medicine in this investigation. This project is a demonstration of the mission of C2SHIP to address some of the most difficult healthcare challenges facing the country."

09:05 EST Astrotech forms subsidiary Pro-Control, enters exclusive license - Astrotech Corporation announces formation of a wholly owned subsidiary Pro-Control and has entered into an exclusive license to use the ATi Mass Spectrometer Technology for chemical manufacturing process control applications. Pro-Control is announcing the introduction of its proprietary Pro-Control Maximum Value Process and the Pro-Control-1000 mass spectrometer designed to test, measure and increase potency, purity and weight yields in the chemical manufacturing processes, delivering value to our customers by facilitating improved yields, which we believe will lead to an overall increase in profitability. Pro-Control MVP uses advanced mass spectrometer instrumentation to monitor and control the fractional distillation of bulk chemicals using real-time in-process samples. Pro-Control MVP provides the vital spectral qualitative and quantitative data needed to control the distillation parameters while significantly improving efficiency. The Pro-Control MVP rapid test can take up to 20 tests per hour providing ideal testing conditions to greatly increase efficiency.

09:03 EST Cadrenal Therapeutics engages Sage Group for development of tecarfarin - Cadrenal Therapeutics announced an engagement with The Sage Group to assist the company in exploring strategic partnerships, co-development and licensing agreements for tecarfarin. The Sage Group provides strategic and transactional advice to healthcare and life science companies in the pharmaceutical, diagnostics, medical devices, biotech, regenerative medicine, and cell and gene therapy fields. This partnership will give Cadrenal access to The Sage Group's clinical and regulatory expertise, capital resources, and network of contacts. Tecarfarin is a novel chemical entity that provides stable anticoagulation to patients with certain orphan diseases, including End-Stage Kidney Disease with Atrial Fibrillation; Left Ventricular Assist Devices; and Antiphospholipid Syndrome. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. The FDA has granted tecarfarin orphan drug and fast-track designations for ESKD with AFib. Cadrenal is also developing expanded regulatory strategies for LVAD and APS.

09:02 EST RTX's Raytheon receives $10M contract from DARPA - Raytheon, an RTX business, has received a $10M contract from DARPA to design and develop a wireless airborne relay system to deliver energy into contested environments. The Persistent Optical Wireless Energy Relay program, known as POWER, aims to revolutionize energy distribution by leveraging power beaming for near-instantaneous energy transport in a resilient, multi-path network. Under the two-year contract, Raytheon will create an airborne relay design to enable "webs" capable of harvesting, transmitting and redirecting optical beams. These "webs" will transmit energy from ground sources to high altitude for the precision, long-range operation of unmanned systems, sensors and effectors. Harvesting energy will ultimately reduce the military's dependence on fuel as well as its delivery and storage.

08:58 EST Getty Images announces partnership with Eric Charbonneau - Getty Images announced an exclusive partnership with leading entertainment photographer, Eric Charbonneau. His extensive archive will be available for license on Getty Images, including his collection of portraiture via Contour. Charbonneau's work has appeared in major publications, as well as books like Vanity Fair's Oscar Night: 75 Years of Hollywood Parties and Tom Ford.

08:52 EST Solitario announces U.S. Forest Service environmental assessment, draft decision - Solitario Resources reported that the U.S. Forest Service published its environmental assessment and draft decision of a Finding Of No Significant Impacts on Solitario's proposed Golden Crest drilling program in South Dakota. This important decision moves the permitting process forward towards the final steps in acquiring drilling approval. Chris Herald, President and CEO of Solitario stated, "We are pleased that the U.S. Forest Service, after careful analysis, including consideration of all stakeholder comments, reached the decision that our proposed drilling program does not result in significant impacts on the environment. Our proposed drilling program was carefully planned with all drilling activities situated on previously disturbed areas of past timber harvesting. Several additional administrative steps remain before final permit decisions will be forthcoming, however, we consider this decision to be the most important milestone before final approval."

08:50 EST 374Water, Inc. partners with DIU, Arcadis, Clean Earth fo PFAS remediation - 374Water announced its participation in an environmental initiative led by the Department of Defense. In collaboration with the Defense Innovation Unit, the project focuses on demonstrating advanced technologies to treat persistent and challenging contaminants known as per- and polyfluoroalkyl substances. These prototype projects are being carried out in collaboration with the DoD's Environmental Security Technology Certification Program, the U.S. Air Force, and the U.S. Navy, spanning three DoD-identified installations. As part of this effort, ten companies, including 374Water, have been awarded prototype contracts to develop and showcase innovative solutions for addressing PFAS contamination. 374Water will employ its AirSCWO technology to demonstrate the destruction of PFAS in various forms. These tests, integral to the project's success, will be conducted at a Clean Earth facility. Arcadis will oversee the project coordination and analytical components, ensuring a comprehensive and collaborative approach to tackling one of the most pressing environmental issues in the United States and the rest of world today.

08:49 EST Verb Technology's MARKET.live adds five retail brands to livestream platform - Verb Technology announces five more new brands have joined the MARKET.live platform this week. The recent completion of the Company's tech integrations with the ecommerce solutions powering thousands of vendors' existing ecommerce stores are continuing to drive demand from retailers eager to create new and additional distribution channels and affiliate relationships through MARKET.live. The Newly Onboarded Brands: DaDa Bedding Collection; elvis+elvin; Joya Mia; Milk Snob; Fat Boy Surf Club.

08:46 EST Ainos announces 1-for-5 stock consolidation - Ainos announced that, as previously authorized by its shareholders, the Company is implementing a consolidation of its outstanding shares of common stock on the basis of one new share of common stock for every five currently outstanding shares. The new shares of common stock will be effective for trading purposes as of the commencement of trading on Thursday, December 14, 2023, and will trade under a new CUSIP number 00902F 303. The Company's ticker symbol, AIMD, will remain unchanged. The Company has filed a Certificate of Amendment to its Restated Certificate of Formation to effect the stock consolidation. The new number of outstanding common shares will be approximately 4,677,898 shares. The number of authorized shares and the par value per share will remain unchanged. No fractional shares will be issued in connection with the reverse stock split. Holders of fractional shares will be paid out in cash for the fractional portion. The number of outstanding options and warrants will be adjusted accordingly, with outstanding options being approximately 7,333 and outstanding warrants being approximately 664,730.

08:44 EST Cellectar Biosciences receives Notice of Allowance for patent for PDC platform - Cellectar Biosciences announced that is has received Notice of Allowance for the patent titled, "Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy," from the Japanese, Chinese, Eurasian, Brazilian, and Mexican patent authorities. These patent allowances in key global regions follow prior allowances for the same patent in the US, Europe, Australia and Canada. The patent provides composition of matter and use protection for the Cellectar's Phospholipid Drug Conjugate, PDC, platform as a targeted delivery vehicle in combination with a class of small molecules known as flavaglines. "The expansion of our global IP portfolio supports our plan to develop a diverse product portfolio delivering value across a broad range of therapeutic modalities beyond radiotherapies. In the immediate term, we look forward to reporting topline Waldenstrom's macroglobulinemia pivotal data for our lead radioconjugate therapy, iopofosine I 131, in January 2024," said James Caruso, president and CEO of Cellectar. "We are also focused on developing and expanding our pipeline of PDCs in additional high need cancers. Our robust global IP portfolio provides the foundation as we drive forward our mission to transform cancer care for people worldwide."

08:42 EST Moderna reports commercial organization changes to prepare for product launches - Moderna announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The Company has decided to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year. To do this, Stephane Bancel, Chief Executive Officer of Moderna, will assume responsibility for sales and marketing in 2024, working directly with the commercial team. To ensure the Company also maintains momentum on its launches beyond 2024, Stephen Hoge, M.D., President of Moderna, will assume responsibility for pipeline commercial strategy and for Medical Affairs. As part of these changes, Arpa Garay, previously Chief Commercial Officer, is expected to leave the Company in the coming months and will remain an advisor during the transition.

08:40 EST Peraso enters new customer partnership for X130 chipset - Peraso announced a new customer engagement. As part of its latest partnership, Peraso's X130 chipset will be replacing its customer's current solution for wireless video distribution for indoor applications. The X130 offers support for high bandwidth, low latency applications and circumvents Wi-Fi network congestion using mmWave.

08:38 EST Barington Capital issues letter to TriMas board - Trimas (TRS) shareholder Barington Capital Group and its affiliates, including The Eastern Company (EML), which collectively own 1.0% of TriMas, has sent a letter to the CEO of TriMas, Thomas Amato, recommending the company implement a plan to improve long-term shareholder value. Highlights of the letter include: "TriMas' shares have underperformed its peer groups, the S&P 600 Industrials Sector Index, the S&P 500 and the Russell 2000...James Mitarotonda, Chairman of Barington, said, "We believe TriMas' poor share price performance is a direct result of the challenges it is experiencing at its Packaging segment and the subscale size of its Aerospace segment. Furthermore, we believe TriMas' multi-segment structure is not delivering long-term value for stockholders, as the sum of TriMas' segments are worth well in excess of its current share price...We propose that TriMas focus its operations on its packaging businesses - the Packaging segment and Norris Cylinder - due to their healthy cash flow characteristics and attractive long-term prospects. We believe our proposal can be implemented by divesting Arrow Engine, as the business is performing at peak levels, and the Aerospace segment, once its margins normalize. We are confident that our proposal can maximize shareholder value, unlocking $42-$54 per share for stockholders over three years or approximately 65%-116% above the company's recent share price."

08:36 EST Sidus Space integrates Edge AI into LizzieSat for initial launch with SpaceX - Sidus Space "is excited to provide an update on its Edge Artificial Intelligence AI software and hardware for space applications expansion. The integration of AI/ML into Sidus' existing offerings enhances and strengthens Sidus' mission to advance satellite technology and expand its solutions for customers. Sidus' investment in AI/ML includes a host of innovative AI software solutions that transform geospatial data into actionable answers. Sidus has successfully integrated AI hardware and software into its LizzieSat satellite design. This new AI software gives Sidus the ability to offer on-orbit tailored solutions to a broader range of customers by providing the resources and expertise to process geospatial data more effectively. "The addition of AI capabilities was a big step forward for our Company," said Carol Craig, CEO and Founder of Sidus. "We have created solutions for customers who were formerly unable to access the kind of technology and the information provided by traditional satellites," continued Craig. "At the same time, we created internal value that will be realized on our own LizzieSats as we plan deployment of satellites over the next two years."

08:35 EST Aditxt to acquire Evofem for $100M in stock - Aditxt (ADTX) and Evofem (EVFM) announced the signing of a definitive agreement under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100M. Pending a successful transaction, it will also mark the establishment of a women's health mission within Aditxt's platform, aligning with global healthcare needs. The boards of directors of both companies have unanimously approved the transaction. Aditxt has assumed Evofem's senior secured debt that was issued to the investor under the securities purchase and security agreement dated April 2020, as amended, and shall pay $5M to Evofem's senior secured debtholder by year-end 2023, $8M by September 2024, and up to an additional $5M thereafter. Aditxt has also agreed to provide a $3M loan to Evofem between the date of signing of the agreement and closing and to cover Evofem's legal costs related to the transaction. At closing, the holders of Evofem's common stock will exchange their shares for an aggregate of 610,000 shares of Aditxt common stock. In addition, Aditxt has agreed to issue up to an aggregate of 89,126 shares of preferred stock to the holders of Evofem's currently outstanding unsecured notes, purchase rights, certain warrants, and preferred stock. Upon closing of the Transaction, which is currently anticipated to occur in the first half of 2024, Evofem will be a wholly owned subsidiary of Aditxt, with the Evofem management team to receive equity grants in the subsidiary of up to ten percent on a fully diluted basis after closing, and will continue to be led by Saundra Pelletier, Chief Executive Officer of Evofem, and the current management team. The boards of directors of Aditxt and Evofem have unanimously approved the proposed Transaction. The transaction is subject to, among other things, the approval of both Aditxt and Evofem stockholders and satisfaction or waiver of the conditions stated in the Agreement.

08:34 EST Greenidge Generation teams with with Infinite Reality, announces GreenidgeAI - Greenidge Generation Holdings announced that it has entered into a partnership and share exchange with Infinite Reality,, the global leader powering virtual immersive experiences serving clients such as Warner Bros. Discovery, Inc., Vodafone Group plc and Universal Music Group N.V. With this transformative partnership, Greenidge is also announcing the launch of its new service offering, GreenidgeAI. GreenidgeAI will be the exclusive provider to iR in the United States and Canada of specialized infrastructure, including datacenters utilizing graphic processing units o support generative Artificial Intelligence workstreams, including metaverse experiences and other applications requiring high performance computing . Additionally, Greenidge and iR will explore jointly designing and building a new datacenter to enhance iR's offerings, spearhead its growth and provide clients with lower-cost GPU access. This effort will be powered by Greenidge's access to low-cost power and leading engineers with experience designing and building datacenters.

08:33 EST Southern Company Executive Chairman Tom Fanning to retire Dec. 31 - Southern Company announced the retirement of Thomas Fanning as the executive chairman of its board of directors, effective Dec. 31. Concurrently, the company also announced the election of Christopher Womack, president and CEO, as the new chairman of the Southern Company Board of Directors, effective Dec. 31.

08:31 EST T. Rowe Price reports preliminary AUM $1.39T at November 30 - T. Rowe Price Group reported preliminary month-end assets under management of $1.39T as of November 30. Preliminary net outflows for November 2023 were $12.6B.

08:29 EST Locafy announces subscription contract from agreement with U.S. media publisher - Locafy Limited announced that it has received its first subscription contract to apply Locafy's Keystone technology with the goal of improving online rankings for existing published advertorials. This contract represents the first order stemming from Locafy's agreement with the U.S.-based diversified media publisher previously announced in June. "Article Accelerator has consistently shown that it can help our customers rise to the top of online search," said Locafy CEO Gavin Burnett. "We believe that there are no alternative SEO solutions available on the market today that can deliver equivalent rapid results in highly competitive markets. After two months of proving our technology's capabilities with this media publisher, this initial contract is a testament to this publisher's confidence in our solution."

08:28 EST Alarum's NetNut announces SERP Scraper API - Alarum Technologies announced the advance Search Engine Results Page Scraper Application Programming Interface, developed by NetNut Ltd., its wholly owned subsidiary. The product, launched in October 2023, marks NetNut's entrance to the data collection and labeling market, estimated at $2.22 billion in 2022, expected to expand at a compound annual growth rate of 28.9%, expected to reach $17.1 billion in 2030. Developed in collaboration with a team of elite intelligence researchers, the new SERP Scraper is the first product developed together and is the first of NetNut's new data collection products line. The Company intends to continue developing its next generation of data collection solutions, catering to the growing need and demand by enterprise customers worldwide.

08:24 EST Boeing receives new order for 40 737 MAX Jets from Avolon - Boeing and Avolon announced the Ireland-based lessor intends to purchase 40 more 737-8 airplanes to expand the lessor's 737 MAX portfolio - consisting of 737-8 and 737-10 variants - to more than 110 jets. Avolon also ordered 40 737-8s in June. The new order is subject to shareholder approval by Bohai Leasing Co, Ltd, Avolon's main shareholder, and will be posted to Boeing's Orders and Deliveries website when finalized.

08:24 EST ZimVie announce compatibility between Vital, Brainlab Spine & Trauma Navigation - ZimVie announced it has received FDA clearance for its Vital Spinal Fixation System including instruments for use with Brainlab Spine & Trauma Navigation. This follows the execution of the companies' Development Cooperation Agreement, announced in March 2023, to achieve compatibility between ZimVie's Vital and Virage systems and Brainlab Spine & Trauma Navigation, which helps surgeons plan and execute spinal procedures, accurately place pedicle screws, and minimize radiation exposure. "This is a positive milestone for both teams and the first of what we hope will be many FDA clearances for compatibility. The strong collaboration between our organizations resulted in an expedited project timeline," said Rebecca Whitney, Global President of ZimVie Spine. "We have been focused on expanding our portfolio with enabling technologies to drive greater adoption, and I am excited to see the team advance toward the launch."

08:22 EST Moderna announces operating model changes, CCO to leave company - Moderna announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The Company has decided to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year. To do this, Stephane Bancel, Chief Executive Officer of Moderna, will assume responsibility for sales and marketing in 2024, working directly with the commercial team. To ensure the Company also maintains momentum on its launches beyond 2024, Stephen Hoge, M.D., President of Moderna, will assume responsibility for pipeline commercial strategy and for Medical Affairs. As part of these changes, Arpa Garay, previously Chief Commercial Officer, CCO, is expected to leave the Company in the coming months and will remain an advisor during the transition.

08:21 EST EDAP TMS announces positive opinion for reimbursement from French HAS - EDAP TMS announced that the French National Authority for Health, HAS, released a favorable recommendation for the reimbursement of high-intensity focused ultrasound, HIFU, therapy in the treatment of prostate cancer. The positive opinion from HAS is an important milestone along the regulatory pathway of securing final reimbursement in France. "We are pleased to receive this positive opinion from the HAS, which we believe reflects the outstanding safety and favorable clinical outcomes from use of Focal One Robotic HIFU in the HIFI study that included more than 3,000 prostate cancer patients," said Ryan Rhodes, Chief Executive Officer of EDAP. "Today's decision brings us one step closer toward securing reimbursement coverage from the French Social Security authorities, as we seek to expand treatment options for physicians and their patients with our leading Focal One HIFU technology platform."

08:20 EST Plus Therapeutics partners with K2bio to develop novel tests for CSF analyses - Plus Therapeutics announced that it has partnered with K2bio to implement novel analysis for cerebrospinal fluid, CSF, tumor and molecular biomarkers for CNS cancers. Initial clinical specimen processing and testing will begin in Q1 2024 in the Company's ongoing Phase 1 ReSPECT-LM trial of rhenium obisbemeda in patients with leptomeningeal metastases. This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas. The Company expects testing costs to be partially covered under this grant. "The initial diagnosis, therapeutic selection and monitoring of patients with CNS cancers such as leptomeningeal metastases are significant problems in everyday clinical practice," said Marc Hedrick, M.D., President & Chief Executive Officer of Plus Therapeutics. "To turn these very lethal CNS cancers into treatable diseases, we must ideally address both the diagnostic as well as the therapeutic needs of caregivers and patients. This partnership with K2bio is the next part of our overall strategy to address both needs in parallel."

08:17 EST NV5 Global awarded $9M geospatial vegetation management contract - NV5 Global announced that it has been awarded a one-year, $9M contract by a Northern California utility for vegetation management designed to minimize vegetation encroachment on the utility's transmission system. During the initial phase of the project, NV5 will utilize advanced remote sensing technologies to identify vegetation encroachment and hazards. Following the initial phase, NV5 will deliver additional midcycle inspections and tree health analytics. "Effective vegetation management is essential to maintaining the safety and reliability of electrical utility infrastructure in the West and across the country," said Dickerson Wright, PE, Chairman and CEO of NV5. "NV5 utilizes the latest technologies and proprietary analytical tools to deliver actionable information to our utility clients and drive strong organic growth for our geospatial solutions."

08:16 EST Spectaire Holdings announces manufacturing financing agreement - Spectaire Holdings announced further details of its balance sheet-light business model in form of manufacturing financing agreements with Viva Capital Funding. The agreement with Viva allows Spectaire to dramatically lower the working capital needs in the production of AireCore units to reach this market. The Company believes this capital-efficient financing structure, together with the outsourcing of manufacturing of AireCore units to Columbia Tech, a subsidiary of Coghlin Companies, creates an asset-light production model that will enable Spectaire to achieve positive free cash flow in a shorter time frame.

08:15 EST Jupiter Acquisition announces intent to reconvene, adjourn Special Meeting - Jupiter Acquisition Corporation intends to reconvene and then adjourn, without conducting any business, the special meeting of stockholders of Jupiter scheduled to reconvene on Tuesday, December 12, 2023, at 12:00 p.m. Eastern Time, until Monday, December 18, 2023, at 12:00 p.m. Eastern Time, as a completely virtual meeting conducted via live webcast. At the Business Combination Special Meeting, once further reconvened, stockholders of Jupiter will be asked to vote on the proposals described in the definitive proxy statement/prospectus filed by Jupiter with the U.S. Securities and Exchange Commission on November 13, 2023, relating to the proposed business combination between Jupiter and Filament Health Corp., a corporation organized under the laws of British Columbia.

08:13 EST UrbanX Air, Eve Air Mobility collaborate for electric air commuter flights - UrbanX Air and Eve Air Mobility (EVEX) have announced plans to bring Urban Air Mobility to Miami by launching electric commuter flights throughout the South Florida area beginning in 2026. This announcement marks a pivotal initial phase in making electric air commuting a reality for South Florida residents with both UrbanX and Eve collaborating closely with local and state officials along with infrastructure, energy and technology providers to establish the necessary framework for launching electric vertical takeoff and landing aircraft flights. The flights will help commuters navigate short distances, avoiding traffic congestion and improving travel times, while providing a safer, faster and more sustainable mode of transportation. In 2022, GlobalX signed a letter of intent to purchase 200 eVTOLs from Eve, a leader in global eVTOL development. With delivery of its first 10 eVTOLs expected in 2026, UrbanX is poised to be the first to bring innovative aircraft technology to South Florida, revolutionizing urban transportation in the region.

08:12 EST TransUnion, Rocketer announce data collaboration to maximize quality customers - Rocketer and TransUnion (NYSE: TRU), today announced the launch of Rocketer Powered By TruAudience, a data collaboration designed to supercharge how insurance companies identify high-value prospects and move them through the sales funnel. Rocketer's proprietary technology combined with TransUnion's TruAudience capabilities provide insurance companies with lookalike audience data to drive increased revenue per user and improved return on ad spend. Rocketer Powered By TruAudience recently completed a digital advertising campaign that delivered unprecedented results for a US-based life insurance company. By utilizing TruAudience data on household income, credit scores, and privacy-first identity resolution, Rocketer identified high-quality prospects and served them ads on social media, reaching an audience that was not only more likely to convert, but had greater potential to turn into high-value customers. "The initial campaign from Rocketer Powered By TruAudience has proven what we have known all along - that identity-driven marketing capabilities deliver impactful results," said Ryan Brooks, vice president of insurance marketing at TransUnion. "Our suite of privacy-first identity resolution, data enrichment, audience targeting, and advanced analytics solutions can be utilized to meet client goals for performance or brand marketing. We're looking forward to continuing this collaboration with Rocketer and helping insurance companies drive maximum value from their ad spend."

08:09 EST Charles River expands 3D in vitro services in agreement with CELLphenomics - Charles River announced that it has entered into an agreement with CELLphenomics. This enhanced offering will provide Charles River clients with access to CELLphenomics' proprietary 3D tumor model platform, PD3D, expanding Charles River's 3D in vitro testing services to further optimize oncological approaches for its clients. CELLphenomics' core competency is the establishment and cultivation of complex patient-derived 3D cell culture models (PD3D) from various solid tumor tissues. These highly reliable, well-annotated and predictive preclinical PD3D models robustly recapitulate the biological properties of the donor tissue, including key histopathological features and genomic makeup. They are a powerful tool for disease modeling, biomarker and drug discovery. CELLphenomics' continuously growing biobank comprises more than 500 complex in vitro models from more than 20 tumor entities, and offers the world's largest collection of complex in vitro models of rare and ultra-rare tumors like sarcomas or thymomas. CELLphenomics has developed a custom mid-throughput screening platform that blends complex cell culture models with advanced automation and a streamlined analysis pipeline. The proprietary, precision medicine PD3D platform offers mid-throughput efficacy testing, drug combination screening, toxicity profiling, target validation, drug sensitivity correlation with clinical response, and biomarker identification. The agreement will also provide CELLphenomics access to Charles River's genomically annotated and in vivo characterized cancer model database to develop PD3D models. The database is comprised of more than 700 tumor models, including PDX, cell lines and cell line-derived xenografts. These models have been profiled for histological features, molecular data, and sensitivity to standard-of-care compounds, allowing a precise selection of suitable tumor models for preclinical anti-cancer agent testing. The biological advantages of PDX include the retention of histological and genetic characteristics of the donor tumor and the preservation of cell-autonomous heterogeneity. The merge of both biobanks will significantly increase the translational relevance of the in vitro and in vivo platforms offered by CELLphenomics and Charles River.

08:08 EST Unity Biotechnology doses first patients in Phase 2 ASPIRE study of UBX1325 - UNITY Biotechnology, announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325, a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema. "Many patients with DME have poor vision despite frequent anti-VEGF injections and there is an urgent need to develop new treatment options for such patients," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "There has been great interest from the physician community in the therapeutic potential of UBX1325, which is based on a novel senolytic mechanism of action, and we are excited to have dosed our first patients in the ASPIRE study. We look forward to sharing initial results from the study in the fourth quarter of 2024."

08:07 EST Bionano announces publication of analytical validation of OGM-Dx HemeOne - Bionano Laboratories announced the publication of a study covering the analytical validation of its laboratory developed test, marketed as OGM-Dx HemeOne. This LDT is based on optical genome mapping analysis of blood or bone marrow samples to detect structural variants of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy. In the study, researchers collaboratively defined a workflow for the analysis of hematological malignancies using OGM, and established protocols for analysis and interpretation using guidelines-based targeted variant assessment, in addition to a whole-genome analysis. The OGM-Dx HemeOne LDT was then validated at one site for concordance, sensitivity, specificity, lower limit of detection, increased diagnostic yield, and assay robustness, using samples from 60 cases with hematological malignancies, 2 cancer cell lines, and 18 controls, generating a total of 215 datasets. Subsequently, the OGM workflow was applied at the other three sites, showing high levels of reproducibility across the sites. Key findings of the analytical validation of the LDT: The OGM-Dx HemeOne LDT demonstrated 100% concordance with traditional methods in the detection of SVs and 100% concordance in the detection of more complicated aberrations, such as translocations and inversions, at or above a 5% variant allele fraction threshold; The OGM-Dx HemeOne LDT was 100% specific and 100% sensitive for the detection of the set of Tier 1 and Tier 2 variants, as defined by World Health Organization and National Comprehensive Cancer Network guidelines for comprehensive evaluation of hematologic malignancies; The OGM-Dx HemeOne LDT resolved structures in complex genomes, effectively consolidating the results of three orthogonal technologies; In 28% of cases, OGM identified additional pathogenic variants not previously reported by traditional methods.

08:07 EST Ekso Bionics receives CMS coding approval for Ekso Indego Personal - Ekso Bionics Holdings announced that the Pricing, Data Analysis, and Coding contractor for the Centers for Medicare & Medicaid Services has completed its review of the Ekso Indego Personal and approved use of Healthcare Common Procedure Coding System Code K1007 to bill Medicare for such device. CMS has proposed a payment level of $94,617 for devices fitting within this code and their final payment determination is expected to be announced in February 2024 and take effect on April 1, 2024.

08:06 EST Blueprint Medicines announces European Commission approval of AYVAKYT - Blueprint Medicines announced the European Commission has approved AYVAKYT for thetreatment of adult patients with indolent systemic mastocytosis with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYTis the first and only approved therapy for people living with ISM in Europe.

08:05 EST Genetic Technologies announces 1-for-100 share consolidation - Genetic Technologies announced its plans to effect: a share consolidation of its ordinary shares of one for one hundred existing Shares and a change of ratio in the Company's American Depositary Share program, comprising a change in the ratio of American Depositary Shares to Shares from one ADS representing six hundred Shares, to one ADS representing thirty Shares. The effective date of the Local Consolidation and Ratio Change is expected to be December 14, 2023. The Shares will continue to be traded on the ASX, under the symbol "GTGDA", from 14 December to 22 December 2023, before reverting to the symbol "GTG" from 27 December 2023. The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol "GENE". On the Effective Date, ADS holders will be required on a mandatory basis to surrender their old ADSs to BNY Mellon for cancellation and exchange at a rate of one 'new' ADSs for every five 'old' ADSs surrendered. Holders of ADSs in the Direct Registration System or in brokerage accounts will have their ADSs automatically exchanged and need not take any action. No fraction of an ADS will be issued. BNY Mellon will attempt to sell any fractions and distribute the cash proceeds to holders. A cancellation fee of $0.022200 per Old ADS surrendered will be charged.

08:05 EST Candel Therapeutics receives FDA fast track designation for CAN-2409 - Candel Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival. "We are pleased with the FDA's decision to grant Fast Track Designation for CAN-2409 in pancreatic cancer," said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. "This milestone follows our first interim data report from the randomized phase 2 clinical trial in patients with borderline resectable PDAC that showed prolonged and sustained survival after experimental treatment with CAN-2409, especially when compared to real-world data on patients receiving radiotherapy treatment. Candel remains on track to release updated overall survival data from the interim analysis of this clinical trial in the second quarter of 2024. We are grateful to the patients, caregivers, investigators and clinical sites that have taken part in this clinical trial."

08:04 EST Curis' licensed emavusertib shows efficacy in lymphoma trial - Curis announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma - PCNSL - patients. As of October 12th, the TakeAim Lymphoma trial has enrolled and treated 19 Non-Hodgkin Lymphoma - NHL - patients, with a combination of emavusertib and ibrutinib; with emavusertib doses ranging from 100 mg to 300 mg BID. The initial data reveal "encouraging" efficacy, demonstrating multiple objective responses in both BTK-naive and BTK-experienced patients. 3 out of 5 evaluable PCNSL patients achieved a Complete Response, with durability ranging from 0.3 - 8.9 months. Consistent with previous findings, the emavusertib/ibrutinib combination demonstrates a manageable and acceptable safety profile, with no observed dose-limiting toxicities in the 200 mg cohort and 2 reversible DLTs in the 300 mg cohort. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib.

08:03 EST Northern Trust appoints Wing Wilson as chief fiduciary officer - Northern Trust has appointed Wing Wilson as chief fiduciary officer, East Region, where she will lead the team in the delivery of fiduciary and advisory services to families, individuals and foundations. In this role, Wilson, who will be based in New York City, will have fiduciary oversight across Northern Trust's East region, spanning from Florida to the New England states. She will lead the strategic direction and execution of these services while accelerating growth.

08:02 EST Intensity Therapeutics names Joseph Talamo as CFO - Intensity Therapeutics announced the appointment of Joseph Talamo as CFO. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Talamo most recently served as Senior Vice President and CFO of HiberCell. John Wesolowski will remain as the company's Principal Accounting Officer and Controller.

08:02 EST PPG opens $17M aerospace application support center in France - PPG announced the opening of a $17M aerospace application support center, or ASC, in Toulouse, France. The facility provides filling and packaging capabilities for aerospace materials, including coatings and sealants for a wide range of aircraft, as well as technical support and a laboratory. The strategic location of ASC Toulouse enables the company to provide faster product deliveries to aerospace customers in southern Europe and North Africa.

07:49 EST Protagonist Therapeutics reports two-year follow up data from REVIVE study - Protagonist Therapeutics announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two-year follow up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera and other disease indications. Ellen K. Ritchie, M.D., Associate Professor of Clinical Medicine at Weill Cornell Medical College presented long-term follow up data from patients in REVIVE who continued into the open label extension. The Phase 2 trial consisted of 3 parts including 70 patients in the dose-finding Part 1, 59 patients in the placebo-controlled, randomized withdrawal Part 2, and 58 patients in the OLE. At the end of Part 2, 69% of rusfertide patients achieved hematocrit control and remained phlebotomy free at 12 weeks, compared to only 19% on placebo. Among the 58 patients that continued into the OLE, as of October 17, 2023, 57 had been treated for over one year and 37 had been treated for over two years. The median follow-up was 2.1 years and data were provided out to 2.5 years in 21 patients. Results showed that rusfertide when added to therapeutic phlebotomy with or without cytoreductive therapy through 2 years resulted in: long-term durable control of hematocrit well below the 45% threshold, decreased red blood cell counts and decreased phlebotomy use; improved and normalized serum ferritin levels; and no new safety signals, with the majority of adverse events being grade 1-2 injection site reactions that decreased in frequency over time, or adverse events consistent with comorbidities anticipated in the PV population Cancers are common in PV patients and in REVIVE, 19 of 70 patients had a history of cancer prior to enrolling in the study. Among these patients, 10 had a history of skin cancer. As of October 17, 2023, there have been 8 patients diagnosed with cancer while on study and 7 with skin cancer. A separate poster presented at ASH by Dr. Naveen Pemmaraju, of MD Anderson Cancer Center titled "Prevalence of Second Cancers in Patients with Polycythemia Vera: A Retrospective Analysis of US Real-World Claims Data," utilized data for 2007-2019 from a large US electronic health records database to examine the overall frequency of secondary cancers in patients with a primary PV diagnosis and compared those who were treated with hydroxyurea versus phlebotomy. None of these patients had received rusfertide. Among the 20,089 PV patients that qualified for this retrospective study: 35.7% of patients reported at least one secondary cancer; 9.1% of patients reported any form of skin cancer; 8.3% of patients reported non-melanoma skin cancer. The mechanisms contributing to the increased risk of cancers in PV patients are not well understood. However, the subset of PV patients treated with HU in this study of real-world claims data had nearly twice the rate of cancers compared to phlebotomy-only treated patients. In an oral presentation, Dr. Andrew T. Kuykendall, of Moffitt Cancer Center in Tampa, FL discussed a real-world retrospective analysis indicating that PV patients experience high rates of arterial and venous TEs. High-risk patients showed a higher risk of death than lower risk PV patients. The study included over 20,000 PV patients in the US via the Optum MarketClarity Database. TE incidence was highest among event-based high-risk patients, followed by age-based high-risk and low-risk patients.

07:40 EST Protagenic Therapeutics reports two-year follow up data from REVIVE study - Protagonist Therapeutics announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two-year follow up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera and other disease indications. Ellen K. Ritchie, M.D., Associate Professor of Clinical Medicine at Weill Cornell Medical College presented long-term follow up data from patients in REVIVE who continued into the open label extension. The Phase 2 trial consisted of 3 parts including 70 patients in the dose-finding Part 1, 59 patients in the placebo-controlled, randomized withdrawal Part 2, and 58 patients in the OLE. At the end of Part 2, 69% of rusfertide patients achieved hematocrit control and remained phlebotomy free at 12 weeks, compared to only 19% on placebo. Among the 58 patients that continued into the OLE, as of October 17, 2023, 57 had been treated for over one year and 37 had been treated for over two years. The median follow-up was 2.1 years and data were provided out to 2.5 years in 21 patients. Results showed that rusfertide when added to therapeutic phlebotomy with or without cytoreductive therapy through 2 years resulted in: long-term durable control of hematocrit well below the 45% threshold, decreased red blood cell counts and decreased phlebotomy use; improved and normalized serum ferritin levels; and no new safety signals, with the majority of adverse events being grade 1-2 injection site reactions that decreased in frequency over time, or adverse events consistent with comorbidities anticipated in the PV population Cancers are common in PV patients and in REVIVE, 19 of 70 patients had a history of cancer prior to enrolling in the study. Among these patients, 10 had a history of skin cancer. As of October 17, 2023, there have been 8 patients diagnosed with cancer while on study and 7 with skin cancer. A separate poster presented at ASH by Dr. Naveen Pemmaraju, of MD Anderson Cancer Center titled "Prevalence of Second Cancers in Patients with Polycythemia Vera: A Retrospective Analysis of US Real-World Claims Data," utilized data for 2007-2019 from a large US electronic health records database to examine the overall frequency of secondary cancers in patients with a primary PV diagnosis and compared those who were treated with hydroxyurea versus phlebotomy. None of these patients had received rusfertide. Among the 20,089 PV patients that qualified for this retrospective study: 35.7% of patients reported at least one secondary cancer; 9.1% of patients reported any form of skin cancer; 8.3% of patients reported non-melanoma skin cancer. The mechanisms contributing to the increased risk of cancers in PV patients are not well understood. However, the subset of PV patients treated with HU in this study of real-world claims data had nearly twice the rate of cancers compared to phlebotomy-only treated patients. In an oral presentation, Dr. Andrew T. Kuykendall, of Moffitt Cancer Center in Tampa, FL discussed a real-world retrospective analysis indicating that PV patients experience high rates of arterial and venous TEs. High-risk patients showed a higher risk of death than lower risk PV patients. The study included over 20,000 PV patients in the US via the Optum MarketClarity Database. TE incidence was highest among event-based high-risk patients, followed by age-based high-risk and low-risk patients.

07:35 EST Abacus Life announces $15M stock repurchase program - Abacus Life announced that its Board of Directors has authorized a new stock repurchase program of up to $15 million of the Company's outstanding common stock over a period of up to 18 months. "We are pleased that our Board of Directors has authorized a stock repurchase program, which reflects our Board's continued confidence in our proven business model and wealth of opportunities, as well as the strength of our balance sheet," stated Jay Jackson, Chairman and Chief Executive Officer of Abacus. "We believe our expert team, wealth of data and innovative technology continue to position us well to execute on our strategic growth initiatives, generate sustained profitability, and ultimately create long-term value for our shareholders."

07:34 EST Streamline Health announces expanded agreement with hospital in Pennsylvania - Streamline Health Solutions announced that it has expanded its agreement with a five hospital, Epic-EHR based health system in Pennsylvania. The system will add eValuator's Pro-Fee pre-bill coding analysis technology to improve revenue integrity and financial performance for their professional fee services. With eValuator, providers can optimize financial performance from their inpatient, outpatient, and professional-fee encounters through one platform, without billing delays. "We are pleased to expand our relationship with this health system and to enable them to audit all of their records, prior to billing, across their continuum of care," stated Ben Stilwill, Chief Executive Officer. "This expansion is a testament to the value of eValuator and to the strong relationships our Client Success team is building."

07:33 EST Ormat Technologies secures 15-yaer energy storage service agreement with SDCP - Ormat Technologies announced the signing of a 15-year Energy Storage Service Agreement, ESSA, with San Diego Community Power, SDCP, California's second largest community choice aggregator, for the 20MW/40MWh Pomona 2 Battery Energy Storage System, BESS located in Los Angeles County, California. The Pomona 2 project, operational since July 2023, represents Ormat's commitment to growing its energy storage segment through the delivery of innovative solutions and storage services. Doron Blachar, CEO of Ormat Technologies said, "This long-term tolling agreement further expands Ormat's energy storage portfolio and supports SDCP's commitment to bringing clean, reliable energy to its nearly one million customers. The Pomona 2 project will help to balance our merchant portfolio and support more stable and profitable revenues for the storage segment. We continue to view energy storage as a unique, multi-year growth sector that will play a vital role in global decarbonization as intermittent renewable energy sources continue to be deployed as part of the ongoing energy transition. Ormat is committed to growing its energy storage portfolio and capabilities by utilizing our market position and expertise, and we are proud to expand our presence in California with this second agreement signed with SDCP. We view California as a key target market for renewable energy development, and are proud to be part of the solution in addressing the state's net-zero goals."

07:31 EST Scinai Immunotherapeutics' psoriasis candidate shows preclinical efficacy - Scinai Immunotherapeutics announced successful preclinical trial results of its innovative anti-IL-17 VHH antibody as a local treatment for the large and underserved population of mild to moderate plaque psoriasis. The study, conducted by Genoskin, a French biotechnology company, aimed to evaluate the anti-inflammatory effects of Scinai's NanoAbs. Genoskin's proprietary human skin models were induced for expression of plaque psoriasis symptoms to enable ex-vivo examination of the therapeutic effects of drugs targeting underlying mechanisms in the pathogenesis of plaque psoriasis. Genoskin's model has been successfully validated as a reliable ex-vivo system for testing drugs aimed at plaque psoriasis. The statistically significant results demonstrated the potential for Scinai's anti-IL-17 NanoAbs to noticeably improve psoriatic skin lesions as indicated by skin viability and structural integrity. These results were further supported by histopathology results demonstrating improved skin structure following a single dose. Results confirm and build upon previously reported results indicating that Scinai's anti-IL-17 NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis. Scinai next intends to conduct an in-vivo proof of concept animal study in early 2024.

07:24 EST Elite Pharmaceuticals announces first shipment of generic Adderall XR to Prasco - Elite Pharmaceuticals announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco. Prasco is, pursuant to the manufacturing and supply agreement dated April 5, 2023 between the companies, a non-exclusive U.S. distributor of the Products. Prasco will market the Products under Burel Pharmaceutical's label, and Elite will manufacture the Products. Elite's product is co-owned with Mikah Pharma.

07:22 EST Integral Ad Science expands Total Media Quality Product to YouTube Shorts - Integral Ad Science (IAS) announced an expansion of its measurement capabilities on YouTube. IAS will now offer its brand safety and suitability measurement product to advertisers for Google's (GOOG) YouTube Shorts inventory, as part of its existing Total Media Quality for YouTube product suite. IAS will now provide additional, third-party assurance for brands that their video ads running on YouTube Shorts are appearing in brand safe and suitable content with video-level transparency, as defined by the Global Alliance for Responsible Media framework and adjacency standards. As part of its Brand Safety and Suitability measurement, IAS also now offers an analytics dashboard for advertisers on YouTube to analyze brand safety and suitability trends with charts and create a custom suitability profile.

07:19 EST Farmland Partners declares 21c per share special cash dividend - Farmland Partners announced that its board of directors has declared a one-time dividend of 21c per share of common stock and Class A Common OP Unit, payable on January 12, 2024 to shareholders of record on December 29.

07:15 EST Laser Photonics receives order for MarkStar Pro Laser Marking System - Laser Photonics Corporation (LASE) received an order from Textron Systems Corporation, a Textron (TXT) company, for its MarkStar Pro laser marking system.

07:13 EST Rogers Communications announces private sale of Cogeco shares - On December 11, 2023, Rogers Communications (RCI) agreed to sell all of the subordinate voting shares of Cogeco Inc. (CGECF) and of Cogeco Communications (CGEAF) owned by it to Caisse de depot et placement du Quebec in a private transaction for an aggregate purchase price of approximately $829M. The shares will be sold for cash at a price of $46.91 per SVS of CGO and $51.40 per SVS of CCA pursuant to a share purchase agreement between RCI and CDPQ. Immediately prior to the sale, RCI will own 5,969,390 SVS of CGO and 10,687,925 SVS of CCA, representing approximately 42.6% of the outstanding CGO SVS and approximately 37.1% of the outstanding CCA SVS, respectively. Following the sale, RCI will own no SVS of CGO or CCA.

07:10 EST Enthusiast Gaming unveils revamp of Shockwave gaming portal - Enthusiast Gaming Holdings announced a significant update to Shockwave.com. The site has relaunched with a fresh new look and mobile-friendly experience. Shockwave.com boasts over 1.4 million active users spending an average of 9 minutes per session on the site, with subscriptions dating back as far as 14 years. With these updates, Enthusiast Gaming aims to position Shockwave.com as a go-to daily game site, while preserving its legacy as one of the oldest gaming sites on the web and capitalizing on its robust library of daily and other casual games.

07:09 EST Lithium Ionic reports assay results for 15 drill holes at Bandeira project - Lithium Ionic reports assay results for 15 drill holes from its Feasibility-stage Bandeira Lithium Project, situated in northern Minas Gerais State, Brazil, in the lithium-rich Aracuai Pegmatite District, also known as the Lithium Valley, where two lithium producers currently operate. Blake Hylands, P.Geo., Chief Executive Officer of Lithium Ionic, commented, "Our most recent drilling efforts at Bandeira, particularly hole ITDD-23-221 and 218, encountered an impressive new zone of high-grade mineralization, clearly highlighting the abundance of spodumene not only on our property but in this district. These results continue to emphasize the robustness of the lithium deposit at Bandeira, which currently represents around 90% of our total resource tonnage but only ~1% of our total property size pointing to the immense potential and scalability of our projects in this lithium-rich region."

07:06 EST Athira Pharma announces results from exploratory Phase 2 trial of fosgonimeton - Athira Pharma announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy Bodies. Fosgonimeton is a potentially first-in-class, investigational, small molecule designed to positively modulate the hepatocyte growth factor system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system. The primary endpoint of SHAPE, a composite score of the change in Event-Related-Potential P300 latency and cognitive assessment, was not met compared with placebo. However, all five patients in the modified intent to treat population treated with fosgonimeton 40 mg once daily saw improvement in ADAS-Cog13 individually and collectively showed a statistically significant improvement compared with placebo. In addition, directional improvements in other cognitive, functional and biomarker measurements were observed in the fosgonimeton 40 mg treatment group. Results for patients in the 70 mg treatment group were inconsistent, potentially due, in part, to a higher dropout rate from baseline enrollment than both the 40 mg and placebo groups. Fosgonimeton was generally well tolerated, with a favorable safety profile. There were no treatment-related serious adverse events or deaths observed in the study. The most common adverse event in the treatment groups was injection site reactions.

07:06 EST Aslan Pharmaceuticals provides update on eblasakimab, farudodstat programs - ASLAN Pharmaceuticals provided a business update and updates related to its programs, eblasakimab and farudodstat. Eblasakimab update: ASLAN is conducting clinical trials of its lead program, eblasakimab, in adult, moderate-to-severe AD patients. In July, ASLAN announced positive topline results from a Phase 2 TREK-AD study that demonstrated eblasakimab's potential as the first biologic in moderate-to-severe AD. ASLAN is also evaluating eblasakimab in the Phase 2 TREK-DX study in dupilumab-experienced, moderate-to-severe AD patients. 63% of dupilumab-treated patients fail to achieve clear or nearly clear skin after 16 weeks, and around half of those patients that do achieve this response do not maintain it after the subsequent 36 weeks. Based on findings from the TREK-AD study, which highlighted the changing patient population in the US, the TREK-DX inclusion criteria have been modified to enroll patients with an EASI score of at least 18 and independent reviewer confirmation of baseline EASI scores has been implemented. US sites are now recruiting according to the updated criteria and additional sites in Europe are expected to open in the first half of 2024. ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024. Farudodstat update: Farudodstat, a highly selective dihydroorotate dehydrogenase inhibitor, is being investigated for the treatment of AA in the FAST-AA Phase 2 trial. Blinded safety data emerging from the study has shown no liver or other major safety concerns to date in patients enrolled supporting farudodstat's improved safety profile compared to the first-generation of approved DHODH inhibitors. Due to the recent increased availability of approved therapies in severe AA and the expansion of the trial to include moderate AA patients, ASLAN expects topline interim data from the study to be available in mid-2024. Corporate updates: ASLAN amended the terms of its loan agreement with K2 HealthVentures. In order to substantially reduce the total payments due to K2 HealthVentures over the next 12 months and extend the date from which the Company is required to make monthly repayments to January 2025, ASLAN made a prepayment of $12.0 million which has been applied to the outstanding principal under the loan agreement. $13.0 million of principal now remains outstanding under the loan agreement. 2024 expected milestones: Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications. topline readout from the TREK-DX study of eblasakimab. Topline interim data readout from FAST-AA study of farudodstat in AA in mid-2024. Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

07:03 EST Ginkgo Bioworks, Arbor Biotechnologies announce collaboration - Arbor Biotechnologies announced a collaboration with Ginkgo Bioworks to leverage Ginkgo's comprehensive Codebase and automated Foundry to jointly optimize Arbor's novel precision editors. Arbor utilizes its computational metagenomic discovery engine and protein engineering expertise to identify and optimize genetic editors with the potential to treat a broad range of genetic diseases. The company's portfolio of novel gene editors has significant therapeutic potential due to, among other things, their unique protospacer adjacent motifs, which may enable access to nearly all sites in the genome, their varied cut types, which can potentially correct a wider range of diseases, their smaller editing technology, which allows the use of additional delivery technologies, and their high specificity, which can enable improved safety profiles. Ginkgo's expertise in high throughput exploration of genetic design spaces complements Arbor's in-house capabilities, and the collaboration is expected to accelerate Arbor's precision editor optimization campaign through massively parallel library design, automated mammalian cell experimentation and iterative AI-guided protein engineering.

07:01 EST ADMA Biologics announces FDA approval of BIVIGAM in pediatric patient setting - ADMA Biologics announced the U.S. Food and Drug Administration, FDA, has approved the Company's supplemental Biologics License Application submitted under section 351 of the Public Health Service Act for BIVIGAM. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of BIVIGAM's prescribing information to expand the primary humoral immunodeficiency indication to pediatric patients 2 years of age and older. "We are pleased to announce that BIVIGAM has received FDA approval for treating PI in patients aged 2 years and older. Previously, the indication for BIVIGAM was restricted to PI patients aged 12 years and older," said Adam Grossman, President and Chief Executive Officer of ADMA. "This expanded label for BIVIGAM allows ADMA to actively address the treatment needs of younger PI patients earlier in their treatment journey. In the periods ahead, we look forward to offering BIVIGAM as an FDA-approved treatment option for these pediatric PI patients," concluded Mr. Grossman.

06:49 EST Pfizer's acquisition of Seagen receives all regulatory approvals - Pfizer (PFE) announces that the waiting period under the HSR Antitrust Improvements Act of 1976 expired December 11, with respect to Pfizer's pending acquisition of Seagen (SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition. Pfizer expects to close the acquisition of Seagen on December 14, subject to the satisfaction of other customary closing conditions. To address FTC concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio in the U.S. to the American Association for Cancer Research. Pfizer also announced changes in its commercial organization to incorporate Seagen. Pfizer will create an end-to-end business organization called the Pfizer Oncology Division, which will integrate certain oncology commercial and R&D operations from both companies and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive VP, and continue reporting to CEO Albert Bourla. Pfizer will split its non-oncology commercial organization into two more focused business divisions: the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive VP, and continue reporting to Bourla; and the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive VP, and will report to Bourla. The new organization structure will go into effect January 1, 2024. Angela Hwang, Chief Commercial Officer, and President, Global Biopharmaceuticals Business will be leaving Pfizer.

06:36 EST Choice Hotels launches exchange offer to acquire Wyndham Hotels & Resorts - Choice Hotels (CHH) announced that it is commencing an exchange offer to acquire Wyndham Hotels & Resorts (WH) in order to present its proposal directly to Wyndham shareholders. Choice continues to believe that a transaction with Wyndham is pro-competitive and would generate value for both Wyndham and Choice shareholders as well as deliver benefits to franchisees, guests and associates of both companies. Choice also announced that it currently holds approximately 1.5M shares of Wyndham common stock, valued in excess of $110M and is filing the Hart-Scott-Rodino, or HSR, notification in order to begin the required regulatory review. The exchange offer maintains the previously proposed offer to Wyndham, comprised of $49.50 in cash and 0.324 shares of Choice common stock per Wyndham share, representing a value of $40.50 based on Choice's trading price as of October 16, the day prior to Choice's first public offer. As of the pre-release date, the proposed offer price equates to a 30% premium to Wyndham's closing share price of $69.10, and reflects a 14.9x multiple of Wyndham's consensus 2023 adjusted EBITDA estimate, a forward multiple Wyndham has never achieved, absent COVID disruptions. The exchange offer provides Wyndham shareholders the opportunity to elect to receive the consideration in all cash, all shares or a combination of cash and shares, subject to a customary proration mechanism. In addition, the exchange offer features a regulatory ticking fee of 45c per Wyndham share per month, equivalent to $38M per month, accruing daily after the one-year anniversary of the date a majority of Wyndham's shares are tendered into the offer. This additional consideration, which has been included so that Wyndham shareholders can receive benefits similar to what Choice previously offered in its November 14 proposal in the unlikely event the transaction were to take longer than 12 months to close, would be payable in cash or stock, at Choice's election, upon Choice's acceptance and exchange of the Wyndham shares tendered into the offer. The exchange offer and withdrawal rights are scheduled to expire at 5:00 PM, New York City time on Friday March 8, unless the offer is extended or terminated. The exchange offer is subject to conditions, including the receipt of all required regulatory approvals. In the exchange offer, Choice is committing to take all actions required by regulators in connection with the approval of the transaction so long as such actions would not have a material adverse effect on the combined company. The full terms, conditions and other details of the exchange offer are set forth in the offering documents that Choice is filing with the Securities and Exchange Commission. Choice made a proposal privately to Wyndham on November 14, comprised of $49.50 in cash and 0.324 shares of Choice common stock per share of Wyndham stock, and offered Wyndham two seats on the combined company's board. The November 14 proposal included certain additional protections for Wyndham shareholders to provide certainty, as Wyndham publicly stated they desired, including: A reverse termination fee of $435M, which represents approximately 6.0% of the total equity purchase price, payable in the event that the transaction did not close due to the failure to receive the required regulatory approvals; A regulatory ticking fee of 0.5% of the total equity purchase price per month, accruing daily after the one-year anniversary of the signing of definitive agreements; A mutual non-disclosure agreement to allow the parties to conduct confirmatory due diligence; and a commitment to taking all actions required by regulators in connection with the approval of the transaction so long as such actions would not have a material adverse effect on the combined company. Instead of discussing the terms of such proposal with Choice, Wyndham publicly rejected the proposed terms on November 21. While not applicable to the exchange offer, in the context of a negotiated transaction, Choice remains willing to offer Wyndham shareholders a reverse termination fee that is consistent with the terms in its November 14, 2023 proposal and two seats on the combined company's board. Additionally, Choice is willing to enter into a mutual non-disclosure agreement to conduct confirmatory due diligence that could potentially unlock additional value for Wyndham shareholders. Choice is starting the clock on the regulatory approval process and is filing notification and report forms under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission. Choice has already met with the FTC on a voluntary basis to discuss the pro-competitive nature of the transaction and looks forward to continuing to work closely with the FTC. Choice is committed to completing the transaction within one year. Choice is actively identifying, evaluating and interviewing highly qualified director candidates to nominate to Wyndham's board and has requested the Directors' & Officers' Questionnaire from Wyndham in accordance with Wyndham's bylaws. Choice intends to nominate a slate of directors to the Wyndham Board of Directors at Wyndham's 2024 Annual Shareholder Meeting.

06:32 EST Transocean announces $251M contract - Transocean announced a minimum 540-day contract for the Transocean Barents with OMV Petrom S.A. in the Romanian Black Sea at a rate of $465,000 per day, excluding additional services. The program is expected to commence in the first quarter of 2025 and is estimated to contribute approximately $251M in backlog, excluding full compensation for mobilization and a demobilization fee. For each day over 540 days, including the two option periods, the operating dayrate will be $480,000.

06:10 EST General Electric-Mytilineos Consortium awarded GBP1B contract for subsea link - GE Vernova's Grid Solutions business and Mytilineos Energy & Metals have been awarded a GBP1B contract by National Grid Electricity Transmission and SP Transmission, part of SP Energy Networks, for the U.K.'s first high-capacity east coast subsea link. Specifically, the GE Vernova-Mytilineos consortium was selected to supply and construct two High-Voltage Direct Current converter stations for Eastern Green Link 1, or EGL1. EGL1 will oversee the construction of a subsea transmission cable from Torness in East Lothian, Scotland to Hawthorn Pit in County Durham, England, enabling the transmission of renewable green energy to power more than two million homes across the UK. GE Vernova, the consortium leader, and Mytilineos will provide the engineering works and technology for the two VSC HVDC converter stations. The design phase will begin in January 2024. Construction will begin in 2025.

06:07 EST Connect Biopharma's rademikibart shows efficacy and safety in Phase 2b trial - Connect Biopharma announced positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma. The trial met its primary endpoint of absolute change from baseline in pre-bronchodilator - BD - forced expiratory volume over one second showing that at Week 12, lung function significantly improved over placebo with both rademikibart doses. The significant improvements seen compared to placebo with both rademikibart 150 mg and 300 mg started as early as Week 1 and were sustained through 24 weeks of treatment. A predefined exploratory analysis showed further improvement in lung function was achieved in patients with eosinophil levels of greater than or equal to 300 cells/microl. Strong and significant improvement in asthma control was also observed. Improvement was evident as early as Week 1 and statistically significant starting at Week 2 through Week 24 for both doses of rademikibart. Treatment with rademikibart showed strong trends toward reduced exacerbations with more than half of all exacerbations during the 24-week study occurring in the placebo group. Treatment with 150 mg and 300 mg Q2W of rademikibart was generally well tolerated. Treatment emergent adverse events were relatively similar across groups, with the most common TEAEs being COVID-19, cough, dyspnea, and wheezing. No new safety signals were observed. The company plans to schedule an End of Phase 2 meeting with the FDA to discuss rademikibart's Phase 3 regulatory path.

06:04 EST NaaS enters charging cooperation with GAC Energy Technology - NaaS together with its strategic partner Kuaidian, has entered into cooperation with GAC Energy Technology, a subsidiary of GAC Group. The parties will, focused on charging service, pool together and share charging station data resources, further improve respective charging service network and provide more convenient charging service to GAC EV owners. As agreed, NaaS and Kuaidian will offer GAC EV owners a host of charging piles and a national charging service network. Cooperation is now underway in smart charging and energy supply, encompassing facets of charging piles connectivity, order data, payment service, etc. In consequence, GAC EV owners will have access to easy charging service via GAC Energy app and mini program, or Aiony/Hyper/Trumpchi app. Besides, Kuaidian app offers "online navigation", "pile search map", "one-click charging" and other features that pile search and charging, alongside a clear view of charging stations nearby.

06:02 EST Perion Network acquires Hivestack for $100M in cash - Perion Network announced that it has completed the acquisition of Hivestack, a global innovative full-stack programmatic digital out of home company. The terms of the transaction include $100M in cash paid upon closing and a 3-year employee retention and performance-based payment plan of up to $25M. Perion financed the acquisition using cash on its balance sheet.

05:55 EST L&T Technology Services secures multi-year engineering services pact with BP - L&T Technology Services (LTTS) has secured a multi-year engineering services partnership with BP (BP). This collaboration underscores LTTS' domain expertise in the Energy segment, focusing on Engineering to drive productivity improvement. The relationship will leverage over 2 decades of LTTS' experience in engineering, manufacturing services, digital and enterprise data management and address some of the most significant challenges for BP globally.

05:47 EST Magnite open new office in Mumbai - Magnite has announced the opening of a new office in Mumbai, which will serve as the company's base across India. The move indicates the company's commitment to providing support for publishers and buyers in one of the fastest-growing digital advertising markets in the world.

05:43 EST Nokia revises 2026 operating margin target ahead of investor event - Nokia will host an investor and analyst event to provide an update on its execution against its group strategy, initial planning assumptions for 2024 and a revised comparable operating margin target for 2026. It will also outline its strategy to give more autonomy to its four business groups. The presidents of Nokia's Mobile Networks and Cloud and Network Services business groups will also present their strategies and future opportunities. Accompanying the move towards more autonomous business groups and to provide investors with greater transparency in assessing their financial performance, Nokia will begin reporting cash flow and regional sales at the business group level in 2024. Tommi Uitto, president of Mobile Networks will present on how MN is revamping its strategy. It has begun to re-baseline its operations for resilience and profitability while maintaining its commitment to technology leadership and protecting its R&D output. These combined actions, to be completed by 2026, will enable MN to achieve a double-digit operating margin at net sales level of approximately EUR 10B, compared to the approximately EUR 11.5B threshold level that would be required. In addition to serving CSP customers, MN will accelerate its offerings to faster growing segments, including Enterprise, Cloud RAN, O-RAN, and the defense sector. As a conclusion to Nokia's long-range planning process, the company has decided to lower its comparable operating margin target to be achieved by 2026 from the prior at least 14% to at least 13%. Nokia still sees a path to achieving the at least 14% comparable operating margin target but considering the current market conditions in Mobile Networks, this is deemed a prudent change. Nokia sees further opportunities to increase margins beyond 2026 and believes this 14% target remains achievable over the longer term. Nokia targets for both NI and CNS to grow faster than the market through 2026 while Mobile Networks will face challenges in 2024 and 2025 before returning to grow faster than the market in 2026. Nokia's other targets remain unchanged.

05:35 EST Icosavax to be acquired by AstraZeneca for $15.00 per share in cash, CVR - Icosavax (ICVX) announced it has entered into a definitive agreement pursuant to which AstraZeneca (AZN), through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax's outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones. The upfront cash portion of the consideration represents an equity value of approximately $838M and a 43% premium over Icosavax's closing market price on December 11 and a 73% premium to Icosavax's volume-weighted average price for the preceding 60 trading days. Combined, the upfront and maximum potential contingent value payments represent, if achieved, an equity value of approximately $1.1B and a 91% premium over Icosavax's closing market price on December 11 and a 130% premium to Icosavax's volume-weighted average price for the preceding 60 trading days. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Icosavax's outstanding shares, and other customary closing conditions and regulatory clearances. Upon the successful completion of the tender offer, a subsidiary of AstraZeneca will be merged with and into Icosavax and any remaining shares of common stock of Icosavax will be cancelled and converted into the right to receive the same consideration per share payable in the tender offer. Subject to the satisfaction of the conditions in the merger agreement, the acquisition is expected to close in the first quarter of 2024.

05:28 EST Sportradar, Tennis Data Innovations enter multi-year agreement - Sportradar and Tennis Data Innovations, or TDI, a specialist joint venture vehicle of ATP and ATP Media, have entered into a multi-year agreement providing the sports technology company with global data and streaming rights for betting, and media data rights, for all ATP Tour and ATP Challenger Tour events. The partnership will focus on driving commercial growth for the sport and enhancing fan engagement opportunities for the downstream market through the development of new betting and media products. Commencing in December 2023, Sportradar's ATP Service+ purpose-built suite of solutions offers new and dynamic ways for fans and bettors to engage with tennis via next-generation, value-add products and services which utilize previously unavailable deep data. ATP Service+ features include augmented streaming, transforming live streams with immersive 3D animations, expanded in-play betting markets, short-form video highlights for registered users and an extensive range of personalized and targeted betting products, to drive sportsbook performance for Sportradar's global network of operator clients. Sportradar will also work with TDI to create products for media as well as utilize Sportradar's OTT solution to stream live match coverage of the ATP Challenger Tour, via ATP's Challenger TV. Additionally, the creation of a joint Tennis Innovation Lab will address emerging opportunities to support ATP's vision. Sportradar will supply Integrity Services for all ATP Tour and ATP Challenger Tour events to safeguard competitions against the threat of betting-related match fixing and corruption, including monitoring and addressing integrity threats and risks through due diligence and investigation support.

05:18 EST Accenture to acquire management consultancy Vocatus, terms undisclosed - Accenture has entered into an agreement to acquire management consultancy Vocatus, which uses behavioral economics modeling to develop pricing strategies and sales concepts for business-to-business and business-to-consumer models. The terms of the acquisition were not disclosed.